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Abstract
Peptic ulcer bleeding is a major clinical emergency. Over the last 10 years
therapeutic endoscopy has been routinely used in selected patients in an attempt to
stop active bleeding and prevent re-bleeding. Trials have shown that endoscopic
therapy reduces re-bleeding, the need for urgent surgery and mortality in patients
with major bleeding from peptic ulcer. Only patients with active bleeding, non-
bleeding visible vessels or tightly adherent blood clot require therapy; the remainder
are at low-risk of further haemorrhage and are treated conservatively. The most
commonly used endoscopic therapies are adrenaline injection and application of the
heater probe, although thrombin injection has theoretical advantages over adrenaline
and there is trial evidence to support its use. Combinations of injection and thermal
treatments may confer additional benefit, but definitive evidence for this approach is
lacking. This thesis is based on a randomised, placebo controlled trial comparing
heater probe plus thrombin injection with heater probe plus placebo injection for the
treatment of high-risk patients with peptic ulcer bleeding.
Two hundred and fifty six patients were randomised. There were nine protocol
violations, and these were excluded from the analysis. One hundred and twenty
seven patients were treated with the heater probe plus thrombin injection; the
remainder received heater probe plus placebo injection. Re-bleeding developed in 19
(15%) of thrombin plus heater probe patients and 17 (15%) of placebo plus heater
probe patients. Emergency surgery was necessary in 16 (13%) and 13 (11%) patients
respectively. Eight patients (6%) in the thrombin group had adverse events compared
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with four (3%) in the placebo group. Eight (6%) of thrombin plus heater probe
patients and 14 (12%) of placebo plus heater probe patients died within 30 days (p =
0.21). These results suggest that the combination of thrombin and the heater probe
does not confer additional benefit over heater probe and placebo as endoscopic
treatment for bleeding peptic ulcer. This trial does not support the use of this
combination of haemostatic therapy.
The Rockall scoring system can be used to predict mortality after gastrointestinal
bleeding, but this score is less good at predicting re-bleeding. The utility of the
system in patients who have undergone endoscopic therapy had not been studied.
Rockall scores were calculated for all patients in the trial and the calibration and
discriminative ability of the scoring system were assessed. The results show that after
endoscopic therapy the score can be used to predict mortality but remains poor for
the prediction of re-bleeding. Patients scoring six or greater should be regarded as
"high-risk."
A detailed score was used to document the extent of comorbid disease in the trial
patients. Outcome was closely related to overall score, higher scores being associated
with re-bleeding, surgery and mortality. The impact of different comorbid conditions
was assessed using logistic regression analysis. Neurological disease and malignancy
were independently associated with re-bleeding. Surgery was required more
commonly in patients with neurological and respiratory conditions, and neurological
disease, respiratory conditions and renal failure were associated with death.
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The heater probe is produced in large diameter (3.2mm) and small diameter (2.4mm)
sizes. It has been suggested that the large diameter probe is most efficacious,
although this is not supported by randomised trial evidence. The trial patients were
analysed according to size of probe used and the outcomes suggest that the two
heater probe sizes are equivalent.
Re-bleeding rates of 15-20% can be expected after initially successful endoscopic
therapy. Accurate prediction of those patients at highest risk could allow for better
use of intensive monitoring. An analysis of clinical and endoscopic factors showed
that the presence of moderate or severe comorbid disease, an ulcer greater than
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Chapter 1
Endoscopic therapy for peptic ulcer haemorrhage - a
review of the literature
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Introduction
Peptic ulcer is the commonest cause of acute non-variceal gastro-intestinal bleeding,
accounting for approximately half of the cases (Fleischer, 1983). Other major causes
such as gastroduodenal erosions, gastritis, oesophagitis, Mallory-Weiss tears, and
vascular malformations are not usually life threatening and respond to conservative
therapy.
Approximately 80% of patients who present to hospital because of acute upper
gastrointestinal bleeding pursue a benign course without re-bleeding in hospital, and
specific intervention is not required in these. The remaining 20% have severe
bleeding due to erosion of a major artery. Most deaths from bleeding arise from this
subgroup. The crude death rate from gastrointestinal bleeding has not significantly
improved over five decades. Avery Jones (1947) reported a hospital mortality of 16%
whilst a large audit of acute gastrointestinal bleeding performed in England in 1995
reported a very similar mortality of 14% (Rockall et al., 1995). This disappointing
observation must, however, be tempered by the fact that the case mix of patients now
admitted is very different to that of previous decades. For example, less that 2% of
patients admitted with acute bleeding in 1947 were aged over 80 years whilst
approximately a quarter of patients currently admitted are octogenarians. There is a
close relationship between increasing age and hospital mortality: increasing age is
inevitably associated with a high prevalence of chronic disease, rendering patients
susceptible to complications following major haemorrhage.
2
Over the past 10 years the treatment of choice for bleeding peptic ulcer in
appropriate patients has been endoscopic therapy, with surgical intervention being
reserved for the failure of therapeutic endoscopy. Nevertheless, optimum
management still relies very much on a team approach with appropriate use of drug
therapy, endoscopic intervention, and surgery. Despite much evidence from
randomised trials, the management of an individual patient still depends on clinical
judgment; experienced endoscopists realise in some cases that attempts at endoscopic
intervention are likely to be fruitless and that surgery is inevitable. Management may
be best undertaken in a specialised "bleeding unit" in which the patient is treated
using agreed protocols and guidelines with endoscopy undertaken once appropriate
resuscitation has been achieved and with management decisions based upon
endoscopic and surgical opinions. Relatively weak evidence derived from
comparison of results in case series with historical controls suggests that this
approach may achieve lower hospital mortality and more efficient use of resources
than management by generalists working in conventional medical or surgical units
(Holman et al., 1990; Sanderson et al., 1990).
Risk stratification
A number of scoring systems have been developed for quantifying the risk of re-
bleeding and death following acute upper gastrointestinal bleeding (Rockall et al.,
1996; Saeed et al., 1993; Pimpl et al., 1987; Garripoli et al., 2000; Guglielmi et al.,
2002). A further report describes a system designed to predict a patient's need for
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treatment of a bleeding episode (Blatchford et al., 2000). Scoring systems are
particularly valuable in the setting of clinical trials and may be of less use in day-to¬
day clinical practice, although some units do employ modified scoring systems to
facilitate clinical decision making.
The Rockall system was developed in the United Kingdom and published in 1996
(Rockall et al., 1996). Independent factors associated with a poor prognosis were
identified from data derived from 4185 patients presenting with acute upper
gastrointestinal bleeding whose clinical course was observed following hospital
admission. The scoring system is summarised in Table 1.1. Whilst the Rockall risk
scoring system performed well when tested in a cohort of patients subsequently
managed in the same geographical area, until recently it has not been widely
validated elsewhere. In a paper published in 1999 the Rockall score was shown to
correlate well with observed mortality, but not re-bleeding, in a Dutch population
(Vreeburg et al., 1999).
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As shown in Table 1.2, Rockall et al. showed a good correlation between the risk
score, re-bleeding and hospital mortality. Deaths following admission to hospital
because of acute gastrointestinal bleeding are rarely due to exsanguination. They are
usually a consequence of postoperative complications when an urgent operation is
undertaken, or due to deterioration of co-morbid conditions.
Table 1.2 Correlation between Rockall score and re-bleeding and mortality
Risk score n Re-bleed (%) Mortality(%)
0 144 7(5) 0(0)
1 281 9(3) 0(0)
2 337 18(5) 1 (0.2)
3 444 50(11) 13(3)
4 528 76(14) 28 (5)
5 455 83 (24) 49(11)
6 312 102 (33) 54(17)
7 267 113(44) 72 (27)
8+ 190 101 (42) 78(41)
Like the Rockall score, the Baylor bleeding score is derived from both clinical and
endoscopic parameters. The score was developed in a much smaller cohort of 80
















































Patients with a post endoscopy score of 10 or less were characterised as low risk, a
score of greater than 10 conferring a high-risk status. The score was prospectively
validated in a small sample of 49 patients treated endoscopically for bleeding peptic
ulcer (Saeed et al., 1995). Re-bleeding in the low risk group was 0% compared with
31% in the high-risk group. The score did not accurately predict rates of surgery and
mortality, but the numbers were too small to make statements concerning these end
points. The Baylor bleeding score has recently been used to target elective repeat
endoscopy and endoscopic therapy to patients with high-risk scores. This approach
has been suggested to be more cost effective than a strategy of repeat endoscopy only
when re-bleeding is clinically apparent (Spiegel et al., 2002).
The scoring system developed by Blatchford et al. (2000) differs from the other
scores in two ways. Firstly, the system was designed to predict a need for
intervention to treat bleeding, rather than to quantify the risk of re-bleeding or death.
Secondly, the score does not include endoscopic findings as a component. Data were
obtained from 1748 patients (the score development group) admitted following upper
gastrointestinal bleeding in the west of Scotland. After logistic regression analysis a
risk score was developed based on the admission haemoglobin, blood urea, pulse,
systolic blood pressure, presentation with syncope, presentation with melaena,
evidence of hepatic disease and evidence of cardiac failure. Intervention was defined
as the requirement for a blood transfusion or endoscopic therapy or surgery to control
bleeding. Increasing scores correlated with an increasing need for intervention in the
score development group. A receiver operator curve was plotted for a subsequent
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internal validation sample of 197 patients, and the score discriminated well with an
area under the curve of 0.92 (95% CI 0.88-0.95). In the paper the numbers of patients
requiring each intervention was not reported. External validation of this scoring
system is required before it can be recommended for clinical use.
Specific therapy
For the 80% of patients who have relatively minor bleeding and who do not have
major endoscopic stigmata of bleeding, supportive therapy including use of
intravenous fluid and the management of co-morbidity (particularly cardiorespiratory
disease) is sufficient.
Patients who present with clinical shock and who at endoscopy have an actively
bleeding peptic ulcer (Figure 1.1) have an 80% risk of continuing to bleed or re-bleed
in hospital (Bornman et al., 1985). Those who have a non-bleeding visible vessel
(Figure 1.2) have a 50% risk of further haemorrhage (Griffiths et al., 1979). Patients
who are found to have an adherent blood clot over the ulcer usually have an
underlying high-risk lesion and should also be regarded as being at considerable risk
of further haemorrhage in hospital. Patients who at endoscopy have a clean ulcer
base or who have black or red spots are at very little risk of re-bleeding.
9
Figure 1.1 Active arterial bleeding from peptic ulcer
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Figure 1.2 Non-bleeding visible vessel
Rim of ulcer
Visible vessel Clot Ulcer base
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It follows from these observations that patients with major endoscopic stigmata
should be considered for specific haemostatic treatment and only such patients
should be included in clinical trials of therapy for gastrointestinal bleeding. This
section will consider those studies that include patients having a non-bleeding visible
vessel, active haemorrhage, or adherent blood clot as entry criteria.
The specific non-surgical approaches to haemostasis are drug therapy and
endoscopic therapy.
DRUG THERAPY
There are three principles underlying the use of drugs as agents which might stop
active haemorrhage and prevent re-bleeding. The first of these is that the stability of
a blood clot is poor in an acid environment (Patchett et al., 1989). Thus agents that
suppress acid secretion, including H2-receptor antagonists (H2RA) and proton pump
inhibitor (PPI) drugs might reduce re-bleeding. The second is that blood clot may be
stabilised by decreasing fibrinolytic activity using agents such as tranexamic acid.
The third approach is that, since major gastrointestinal bleeding is due to arterial
erosion, reduction of arterial blood flow by agents such as somatostatin and
octreotide could achieve haemostasis and prevent re-bleeding.
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Acid suppressing drugs
The efficacy of H2RA in the management of acute upper gastrointestinal bleeding
has been assessed in randomised trials (Walt et al., 1992; Collins and Langman,
1985). Unfortunately, no trial has shown benefit in terms of reduction of re-bleeding
incidence or mortality.
Experience involving the use of PPIs is inconsistent, but recent evidence supports
their use after endoscopic therapy. The largest trial involved 1147 patients who were
randomised to receive intravenous, then oral omeprazole or placebo (Daneshmend et
al., 1992). No significant difference in hospital mortality, operation rate or re-
bleeding was demonstrated (Table 1.4). The study was not restricted to the high-risk
patients who had endoscopic stigmata of recent haemorrhage. Accordingly, event
rates were rather low in the placebo group, and this may have limited the power of
the study to show a difference.
Khuroo et al. (1997) randomised 220 bleeding ulcer patients who had major
endoscopic stigmata to receive high dose oral omeprazole or placebo. Although all
patients had major stigmata of haemorrhage, 57% of patients were reported to have
adherent clot in the ulcer base. Re-bleeding, the need for urgent surgery, blood
transfusion, and mortality were all reduced in the patients receiving omeprazole
(Table 1.5). The number of patients needed to treat with omeprazole to prevent one
death was 25, and to prevent one operation was seven. This trial has been criticised
because it included relatively young patients with relatively little co-morbidity and,
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because endoscopic therapy was not administered to any patient. The observation
that omeprazole reduced re-bleeding and surgery rates when no endoscopic therapy
was performed suggested a beneficial effect of the PPI. This might be explained by
the fact that the majority of patients in both groups had ulcers containing adherent
clot.




Re-bleed (%) 77(15) 91 (17)
Operation (%) 56(11) 57(11)
Death (%) 35(7) 29 (6)
Gastric ulcer
n 97 93
Re-bleed (%) 26 (27) 23 (25)
Operation (%) 18(19) 16(17)
Death (%) 7(7) 5(5)
Duodenal ulcer
n 149 164
Re-bleed (%) 32 (21) 47 (29)
Operation (%) 27(18) 34 (21)
Death (%) 16(11) 8(5)
Source: Daneshmend et al., 1992
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Table 1.5 Omeprazole vs placebo for bleeding peptic ulcer
Outcome Omeprazole (n = 110) Placebo (n = 110) P
Re-bleed (%) 12(11) 40 (36) <0.001
Surgery (%) 8(8) 26 (23) <0.001
Transfusion (mean units) 2.3 4.1 <0.001
Death (%) 2(2) 6(6) NS
Source: Khuroo et al., 1997
Two trials published back to back in the Scandinavian Journal of Gastroenterology
examined the use of high dose intravenous omeprazole after endoscopic haemostasis
(Schaffalitzky de Muckadell et al., 1997; Hasselgren et al., 1997). All patients had
major peptic ulcer bleeding, but as in the trial by Khuroo half the patients had
adherent clot as the reported stigma of haemorrhage. The conclusions were that
intravenous omeprazole infusion for three days following endoscopic therapy
improved outcome. Both trials used composite end-points which were complex and
ill defined and were discontinued early due to an unexplained imbalance in mortality
in one of the trials (Hasselgren et al., 1997), this reducing their overall impact.
Villanueva et al. (1995) randomised 86 patients following successful endoscopic
haemostasis for peptic ulcer bleeding to either intravenous omeprazole or ranitidine.
There were no differences between the groups for the end-points of re-bleeding,
surgery or death. In contrast, a similar small trial by Lin and colleagues (1998)
concluded that intravenous omeprazole was superior to cimetidine in terms of
reduction of re-bleeding rates, but not those of surgery or death.
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The most important trial was performed by Lau et al. (2000) and published in the
New England Journal of Medicine. Two hundred and forty patients in whom
endoscopic therapy for major ulcer bleeding had been successful were randomised.
All patients had high-risk ulcers with active bleeding or non-bleeding visible vessels,
and were treated by adrenaline injection followed by heater probe
thermocoagulation. Adherent clots were removed to allow therapy to the underlying
vessel. Patients then received either an 80mg bolus dose of intravenous omeprazole
followed by an infusion of 8mg per hour for 72 hours or placebo. Re-bleeding rates,
blood transfusion requirements and length of hospital stay were significantly reduced
in the omeprazole group compared to placebo. There was a trend toward fewer
operations and deaths in the omeprazole group, but this did not achieve statistical
significance. (Table 1.6)
Table 1.6 Omeprazole vs placebo for bleeding peptic ulcer treated with
endoscopic therapy
Outcome Omeprazole (n = 120) Placebo (n = 120) P
Re-bleed (%) 8(7) 27 (23) <0.001
Surgery (%) 3(3) 9(8) 0.14
Transfusion
(mean units +/-SD)
2.7 +/- 2.5 3.5 +/- 3.8 0.04
Length of stay < 5 days
[number of patients (%)]
56 (47) 38 (32) 0.02
Death (%) 5(4) 12(10) 0.13
Source: Lau et al., 2000
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Following the publication of the trial by Lau, the use of high dose intravenous PPI
after successful endoscopic therapy for bleeding ulcer has become standard
management in many centers in the UK and Europe. The 80mg bolus and 8mg per
hour infusion regimen consistently raises intragastric pH above six for the majority
of a 24 hour period (Hasselgren et al., 1998). It is not known, however, whether this
optimum regimen is actually necessary following endoscopic therapy, and whether
bolus intravenous or even oral PPI would suffice. Two small studies have attempted
to answer these questions.
Udd et al. (2001) randomised 142 patients with ulcer bleeding to the high dose three-
day intravenous omeprazole regimen or to a single daily bolus dose of 20mg for
three days. Rates of re-bleeding (8% for high dose vs 12% for standard dose),
surgery (4% vs 7%) and death (6% vs 3%) were comparable between the groups.
Only 102 patients had required endoscopic therapy, and approximately 30% of
patients had an ulcer with a black base only. Thus the number of high-risk ulcers in
the trial was small, the event rates were low and its conclusions can be questioned.
The effect of oral Omeprazole following endoscopic therapy for bleeding peptic
ulcer was studied by Javid et al. (2001). One hundred and sixty six patients with
ulcers which were actively bleeding, had non-bleeding visible vessels or adherent
clots were treated with a combination of 1:10,000 adrenaline plus 1% polidocanol
injection. They were then randomised to receive oral Omeprazole 40mg bd or
placebo. Six (7%) of the 82 patients in the omeprazole group re-bled compared with
18 (21%) of the 84 patients in the placebo group (p = 0.02). Surgery was required in
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two patients in the omeprazole group and seven patients in the placebo group (p =
0.17). One death occurred in the omeprazole group compared to two in the placebo
group. The results are comparable to those achieved by Lau with the high dose
intravenous regimen (Lau et al., 2000). It should be noted, however that 40% of
patients in this trial had ulcers with adherent clot, and the number of patients with
high-risk lesions was therefore lower than that in the Hong Kong study. A further
high quality trial comparing the use of intravenous and oral omeprazole in high-risk
ulcer bleeding patients is now required.
The evidence now supports the use of PPIs following endoscopic haemostasis in
patients with major peptic ulcer bleeding. All the trials show a trend towards
reduction in re-bleeding in omeprazole treated patients although rates of surgery and
mortality are not convincingly reduced. The trials are rather heterogeneous and few
in number, this making meaningful meta-analysis difficult. Zed et al. (2001)
performed an analysis of nine trials comparing PPIs with placebo or H2RA.S given
after endoscopic therapy. The conclusion was that PPIs are superior to placebo and
H2RAS in terms of reduction of re-bleeding and surgery. Mortality was not reduced
in the PPI groups. A second meta-analysis by Gisbert et al. (2001) included 11 trials
and reached similar conclusions although the beneficial effect of PPI was found only
to reduce re-bleeding. The group also noted that PPIs were most likely to be
beneficial in patients with active bleeding and non-bleeding visible vessels, and in
those patients who did not receive endoscopic therapy. It is not certain that use of
PPIs saves lives, but the effect on surrogate markers such as re-bleeding, transfusion
requirements, surgical operation and endoscopic intervention are convincing. There
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do not appear to be significant hazards associated with the drugs and their cost in the
context of an acutely bleeding patient is relatively minor.
Tranexamic acid
A meta-analysis of six controlled trials, which included 1267 patients, did not show a
significant reduction in the rate of re-bleeding, but did show a reduction in the need
for surgery and in mortality, which reached statistical significance (Henry and
O'Connell, 1989) (Table 1.7). This meta-analysis included trials in which many
patients did not have major endoscopic stigmata of bleeding. Therefore, the results
may not be applicable to patient populations at greatest risk.
Table 1.7 Tranexamic acid for gastrointestinal bleeding - a meta-analysis
Outcome Odds Ratio 95% CI P
Re-bleeding 0.80 o77© 0.13
Operation 0.72 0.52-1.00 0.047
Death 0.60 0.40-0.89 0.01
Source: Henry and O'Connell, 1989
The largest study investigating the use of tranexamic acid was undertaken by the
Nottingham group (Barer et ah, 1983). Seven hundred and seventy-five patients
presenting to hospital because of acute gastrointestinal bleeding were randomised to
receive oral cimetidine, tranexamic acid or placebo. No significant difference in
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bleeding or operation rates was demonstrated, but there was a rather surprising large
difference in mortality. Mortality was 7.7% in cimetidine treated patients, 6.3% in
tranexamic acid treated patients, and 13.5% in placebo. The mortality rate of 13.5%
in the placebo treated group is greater than that expected for conservatively treated
patients based on the results of other studies. Furthermore, other studies do not
demonstrate benefit from the use of cimetidine. It is possible that more high-risk
patients were inadvertently randomised to the placebo group in this study.
Somatostatin and octreotide
Somatostatin and its analogs have two actions which are theoretically valuable in the
management of ulcer bleeding, namely inhibition of acid secretion and reduction of
splanchnic blood flow. Mesenteric blood flow falls dramatically during infusions of
somatostatin but it is not clear whether this is principally due to vasoconstriction of
major blood vessels or peripheral arterioles.
There have been 14 controlled trials of somatostatin versus other therapy in the
management of patients presenting with acute gastrointestinal bleeding (Sommerville
et al., 1985; Magnusson et al., 1985; Basso et ah, 1986; Corragio et ah, 1984;
Corragio et ah, 1989; Galmiche et ah, 1983; Saperas et ah, 1988; Kayasseh et ah,
1980; Antonioli et ah, 1986; Tulassay et ah, 1989; Torres et ah, 1986; Wagner et ah,
1983; Goletti et ah, 1992; Christiansen et ah, 1989). Two meta-analyses suggest that
somatostatin but not octreotide has a primary haemostatic role and reduces the need
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for surgical intervention (Jenkins et al., 1998; Imperiale and Birgisson, 1997).
However, scrutiny of the relevant trials reveals many problems. Many of the studies
were small and inclusion criteria varied widely from gastritis to major active
bleeding.
The largest trial was reported by Sommerville et al. in 1985 (Table 1.8). Six hundred
and thirty of 779 potentially eligible actively bleeding patients were randomised to
receive somatostatin (a bolus of 250 mg followed by 250 mg hourly for 72 hours) or
a placebo. No significant differences in re-bleeding, operation rate, and mortality
were demonstrated between the treatment groups. The authors also reported the
subgroup analysis of patients who had bled from gastric or duodenal ulcers. There
were similar numbers of these in both active and placebo arms. Unfortunately the
presence or absence of major stigmata of bleeding were not reported. The operation
rate, mortality, and re-bleeding rates were similar in the two groups. However, a
statistically significant difference in mortality in duodenal ulcer patients was
demonstrated, with more actively bleeding patients dying. Although this is a large
study, and patients were randomised early, the possible efficacy of somatostatin may
have been difficult to demonstrate because of the inclusion of many patients whose
prognosis was excellent because they had relatively trivial bleeding or, at the other
end of the spectrum, inclusion of patients in whom operation and possibly death was
inevitable because bleeding was so severe.
21




Re-bleed (%) 70 (22) 89 (28)
Operation (%) 35(11) 34(11)
Death (%) 31 (10) 25 (8)
Gastric ulcer
n 57 57
Re-bleed (%) 18(32) 21 (37)
Operation (%) 10(18) 5(9)
Death (%) 4(7) 7(12)
Duodenal ulcer
n 77 81
Re-bleed (%) 21 (27) 31 (38)
Operation (%) 13 (17) 18(22)
Death (%) 15(19) 5(6)*
Source: Sommerville et al., 1985
*
p <0.02.
A smaller study with contrasting results was reported by Magnusson et al. (1985)
(Table 1.9). This trial only included patients who were clinically shocked due to
active bleeding from peptic ulcers. Patients were randomised to receive somatostatin
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or placebo infusion. Uncontrolled haemorrhage and need for surgical operation were
commoner in placebo then somatostatin treated patients. However, the rates of
mortality and re-bleeding were similar in both groups and the apparent difference in
transfusion requirements was not statistically significant. This small study lacked the
power to demonstrate a significant difference in mortality should a true difference
exist.
Table 1.9 Somatostatin vs placebo for acute gastrointestinal bleeding
Somatostatin Placebo
n 46 49
Peptic ulcer bleeding 36 42
Stigmata ofmajor bleeding 38 41
Continued bleeding (%) 8(17) 16(33)
Operation (%) 5(11) 14(29)
Re-bleeding (%) 6(13) 5(10)
Median transfused units 5.8 7.2
Death (%) 4(9) 1(2)
Source: Magnusson et al., 1985
Currently, the evidence for routine use of somatostatin is weak and further studies




Endoscopic stigmata of haemorrhage
Endoscopic stigmata of haemorrhage are seen in 20% of patients with peptic ulcer
bleeding. Endoscopic therapy is only required when active bleeding, a non-bleeding
visible vessel or adherent blood clot is present. Major ulcer bleeding is due to erosion
of a submucosal artery. The affected artery may course for a considerable distance in
the submucosa beneath the ulcer floor, and the potential endoscopic target is,
therefore, sometimes relatively large. The majority of involved arteries are less than
2mm in diameter, and in 83% of cases there is arteritis and fibrinoid necrosis of the
vessel wall, with associated aneurysmal dilatation of the artery in 52% (Swain et al.,
1986). This pseudoaneurysm may bulge into the floor of the ulcer and is often
associated with overlying blood clot. (Figure 1.3) Recanalised thrombus is seen in
24% of specimens. Less commonly, direct invasion of non-aneurysmal arteries
occurs. The "visible vessel" which is the target for endoscopic injection thus
comprises a true artery, a pseudoaneurysm or a clot plugging a defect. This area is
clearly unstable and intervention may disrupt the fragile arterial wall, risking further
major bleeding.
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Figure 1.3 Pathology of the visible vessel
Gut lumen Thrombus Arterial wall
Submucosa
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Mechanism of action of endoscopic therapy
Many endoscopic treatments have been used for ulcer bleeding. The endoscopist
attempts to stop bleeding and prevent re-bleeding by causing a stable blood clot to
form at the site of the eroded artery. Unfortunately neither examination of resected
specimens or animal models define how this occurs. There are nevertheless three
basic approaches to endoscopic therapy (Table 1.10).



















Thermal approaches involving laser, the heater probe and electrocoagulation by
monopolar or bipolar probes attempt to induce thermocoagulation with thrombosis of
the bleeding point. In experimental bleeding ulcers these approaches are more
effective than injection treatments (Hepworth et ah, 1998; Rutgeerts et ah, 1989).
Resected ulcers are rarely available for histological examination however, and the
putative effects of injection therapy including thrombosis, endarteritis, oedema and
acute inflammation are inherent features of chronic ulcer disease. Available animal
models are based upon acute mucosal injury, and this has important differences to
bleeding from peptic ulcers, which are the consequence of a chronic inflammatory
process eroding a major artery. Studies based upon animal models which imply that
injection therapy for ulcer bleeding is likely to be ineffective (Hepworth et al., 1998;
Rutgeerts et ah, 1989) are to be treated with skepticism. Clinical trials have
conclusively shown that endoscopic therapy improves prognosis in ulcer bleeding
patients, and it is probable that the available animal models are generally
unsatisfactory.
The proposed mechanisms by which injection therapy stops ulcer bleeding and
prevents re-bleeding are as follows:
1. Tamponade
Injection of fluid into the confined compartment of a rigid and fibrotic ulcer base
may compress and therefore apply tamponade to the bleeding vessel. Trials by Lai et
ah (1994) and Fleig (1994) support this hypothesis, reporting that endoscopic
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injection ofwater was as effective at stopping bleeding as 1:10,000 adrenaline. These
results are further supported by the study reported by Lin et al. (1993) who compared
injection of normal saline, 3% NaCl solution, 50% glucose/water solution and pure
alcohol in 200 patients with actively bleeding ulcers or non-bleeding visible vessels.
There were no statistical differences between rates of initial haemostasis, re-
bleeding, and surgery for any group. (Table 1.11) Larger injected volumes were
required to achieve initial haemostasis in the saline and glucose/water groups,
suggesting that tamponade was an important factor.
Table 1.11 Endoscopic injection for the arrest of peptic ulcer haemorrhage






n 50 50 50 50 -
Volume injected (ml)
(Mean +/- SD)





41(82) 45 (90) 43 (86) 46 (92) p>0.1
Re-bleed (%) 3(7) 11(24) 6(14) 5(11) p>0.1
Surgery (%) 5(10) 7(14) 4(8) 3(6) p > 0.1
Source: Lin et al., 1993
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These results are challenged by those reported by Laine and Estrada (2002). In this
study patients with high-risk ulcers were randomised to injection of normal saline
(n= 48), or to bipolar electrocoagulation (n=52). Twenty nine percent of patients in
the saline group re-bled compared with 12% of those treated with the BICAP. The
saline patients required significantly more blood, but there were no differences in the
duration of hospital stay or mortality.
The contribution of a tamponade effect is probably related to the degree of fibrosis in
the ulcer base and the volume of fluid injected. It is not known whether injection can
generate sufficient pressure to tamponade a bleeding artery. Any effect probably
occurs at the time of injection, and the duration of action is unknown.
2. Vasoconstriction
Dilute adrenaline causes vasoconstriction. In both animal models of acute mucosal
injury and in clinical trials, adrenaline has been shown to have a haemostatic benefit.
Arteries within or adjacent to ulcers contain sufficient smooth muscle, with little
atheroma (Swain et al., 1986) but vasoconstriction may be impaired by surrounding
fibrosis. Injection of adrenaline is usually performed in a circumferential manner to
cause constriction of arteries feeding the bleeding site. Endarteritis and arterial
thrombosis do not occur as a direct result of adrenaline injection (Rajgopal et al.,
1992), but large injected volumes (often up to 20ml) may have a significant
tamponade effect.
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The vasoconstrictive effects of injected adrenaline are likely to be short lived,
although in experimental models vasoconstriction may persist for at least five
minutes after injection (Rajgopal et al., 1992). It is possible that the temporary
haemostasis occurring as the result of vasoconstriction may facilitate clot formation.
It is also possible that other important effects, including alteration of platelet function
(O'Brien, 1963) and stimulation of the coagulation cascade contribute to the efficacy
of adrenaline injection.
3. Thrombosis
Both tamponade and vasoconstriction are presumed to be temporary effects, with a
more permanent seal of the arterial defect supervening to prevent recurrent bleeding.
Thrombosis is probably a consequence of tamponade and vasoconstriction, since in
clinical trials adrenaline injection reduces re-bleeding in addition to achieving
primary haemostasis. Direct formation of a clot using thrombin or fibrin glue is also
effective. Pescatore et al. (1998) examined 20 specimens from patients who had
required resection after injection treatment with fibrin glue. Resection occurred
between six hours and nine days after injection. The ulcer was identified in 15
specimens, with no fibrin deposits found in three, sparse deposits in eight and large
deposits in four. With increasing time after injection, the initial clot was replaced by
fibroblast rich granulation tissue. This study gives some insights into events after
fibrin glue injection, but as the specimens were all from patients in whom the
injection therapy failed, its results can not be extrapolated to those patients who do
not re-bleed. Further studies are needed.
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4. Sclerosis
Sclerosant injections cause deep ulceration, tissue necrosis and venous thrombosis.
Arteritis and arterial thromboses are infrequent (Rajgopal et ah, 1992; Kubba et ah,
1997). These histological effects occur some time after injection and it has been
suggested that the main benefit of sclerosants is prevention of re-bleeding. As
discussed elsewhere, there are concerns regarding their clinical use since in practice
sclerosants provide no greater benefit in terms of re-bleeding than adrenaline
injection alone, and because their use may cause extensive local necrosis (Rajgopal
et ah, 1992; Kubba et ah, 1997; Randall et ah, 1989).
5. Dehydration
Injection of absolute alcohol results in tissue dehydration with surrounding
inflammation, necrosis, ulceration and vessel thrombosis (Randall et ah, 1989).
Trials using alcohol again show benefit over conservative therapy, but this is at the
risk of considerable tissue damage.
The optimum volume of injection is not known. Small volumes of alcohol and
sclerosants are required in order to minimise the risk of perforation. Much larger
volumes of saline and adrenaline can be used without complication. In the trial by
Lin et ah (1993) discussed above, the mean injection volume in the saline group was
15ml. Laine and Estrada (2002) injected a mean volume of 30ml. A further trial by
Lin et ah (2002) compares large with relatively small volume injection. One hundred
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and fifty six ulcer bleeding patients were randomised to injection of 5-10ml of
adrenaline (the small volume group) or injection of 13-20ml (the large volume
group). Re-bleeding occurred in 31% of the small volume patients compared with
15% in the large volume group. The other usual end-points were similar. The
conclusion of this trial was that larger volume injections of adrenaline are safe and
more likely to prevent re-bleeding than injection of a smaller volume.
Mechanical clips, staples, and sewing attempt to produce haemostasis by clamping
the bleeding arterial lesion.
Clinical trials
Many clinical trials of endoscopic therapy for non-variceal bleeding have been
published. The quality of these trials varies greatly. In general, the number of
patients randomised in any one study is small and clinicians managing the patients
have not been blinded to the type of endoscopic therapy.
Thermal methods
LASER PHOTOCOAGULATION
Lasers were the first endoscopic therapeutic modality shown to be effective in
managing acute non-variceal gastrointestinal bleeding. Initial experience involved
the use of argon lasers but it subsequently became clear that the tissue characteristics
of thermal injury achieved by the Nd-YAG laser were more appropriate. In fact,
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clinical trials showed little difference in outcome in series involving argon or Nd-
YAG laser treatment. There have been three randomised trials comparing argon laser
therapy and conservative therapy for bleeding peptic ulcer (Vallon et al., 1981;
Swain et al., 1981; Jensen et al., 1984) and a further nine trials of Nd-YAG laser
treatment (Swain et al., 1986; Krejs et al., 1987; Rhode et al., 1980; Rutgeerts et al.,
1982; MacLeod et al., 1983; Homer et al., 1985; Trudeau et al., 1985; Buset et al
1988; Matthewson et al., 1990) (Table 1.12). Most of these studies show that laser
treatment significantly reduced the rates of re-bleeding, transfusion requirement, and
operation rate. One trial showed significant improvement in hospital mortality
(Swain et al., 1986). However, experience has not been universally positive with
laser treatment. It is revealing to compare the best performed study with a large
American multicenter study, published in the New England Journal of Medicine.
Swain et al. (1986) randomised 138 patients to laser treatment or conservative
therapy. He personally undertook all endoscopic examinations and treatments and
was responsible for the clinical management of the treated subjects. His study
showed significant reduction in re-bleeding, need for emergency surgery, and
mortality in laser treated patients. In contrast Krejs et al. (1987) randomised a similar
number of patients to laser therapy or to conservative treatment. Patients treated by
laser tended to have a poor outcome compared to control patients. It was apparent in
this study that endoscopic therapy was undertaken by a large number of endoscopists
who varied in their expertise. Of all therapeutic endoscopic modalities, laser therapy
is the most difficult to use. Even in Swain's hands up to 17% of ulcers could not be
treated. The method is a "no touch" one and an awkwardly placed duodenal ulcer
within a deformed duodenum may be extremely difficult to adequately treat. Thus
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the results in the hands of relatively inexperienced therapeutic endoscopists, each
performing few procedures, was likely to have been variable. Furthermore, the
patients included in this trial were managed in many units, rather than by a single
"bleeding team".
Endoscopic laser therapy has been found to be relatively safe with few
complications; in particular, gastrointestinal perforation has been rare. However,
since the technique is difficult, relatively expensive and because other approaches are
at least as effective, laser therapy for peptic ulcer bleeding is no longer used.
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Table 1.12 Nd-YAG trials for bleeding peptic ulcer
Study Group n Re-bleed (%) Surgery (%) Mortality (%)
Swain, 1986 Laser 70 7(10) 7(10) 1 (1-4)
Control 68 27 (40) 24 (35) 8(12)
Krejs, 1987 Laser 85 19(22) 14(16) 1 (1-2)
Control 89 18 (20) 15(17) 1(1.1)
Rhode, 1980 Laser 62 37 (59) 8(13) 15(24)
Control 43 24 (57) 18(41) 12 (27)
Rutgeerts, 1982 Group 2: L 46 3(7) 1(2) 6(13)
Group 2: C 40 6 (15)a 5(13) 6(15)
Group 3: L 17 3(18) 2(12) 2(12)
Group 3: C 26 8(31) 6(23) 4(15)
MacLeod, 1983 Laser 21 6(29) 5(24) 1(5)
Control 24 8(33) 8(33) 2(8)
Homer, 1985 Laser 17 3(18) — 0(0)
Control 25 8 (32) — 2(8)
Trudeau, 1985 Laser 18 2(11) 1(5) 2(11)
Control 15 6(40) 4(26) 5(33)
Buset, 1988 Laser 42 10(24) 3(7) 1(2)
Control 46 17(37) 2(4) 2(4)
Matthewson, 1990 Laser 44 9(20) 9(20) 1(2)
Heater probe 57 16(28) 13 (22) 6(10)
Control 42 18(43) 13 (30) 4(9)
a6 of 31 where bleeding stopped.
Rutgeerts group 2: active non-spurting bleeding.
Rutgeerts group 3: inactive bleeding with stigmata of recent haemorrhage.
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HEATER PROBE
The heater probe transmits preset amounts of energy to the bleeding point via a
Teflon tipped catheter. A powerful water jet is used to clean the ulcer base, help
visualize the bleeding point and prevent the probe sticking to the bleeding point.
Haemostasis is achieved by coaptive coagulation, using both tamponade and the
application of heat. Best results are said to be achieved using large sized probes.
There have been three trials in which the heater probe has been compared to
conservative therapy (Fullarton el al., 1989; Jensen et al., 1988; Jaramillo et ah,
1993). All showed benefit in terms of further bleeding, and surgery, and one
published only in abstract form (Jensen et al., 1988) demonstrated a trend towards
reduction in mortality (Table 1.13).
The heater probe is "user friendly". Its capacity to apply thermal energy by tangential
application and its powerful water jet are particular advantages. Perforations have
occurred following treatment, although these are unusual, and are generally of the
order of 1% (Wong et al., 2002). Questions remain concerning the amount of energy
that should be applied. In general, medium power settings (20 - 30 Joules) are used
but it is not possible to be prescriptive concerning the total amount of energy that
should be given. Most authorities consider that treatment should be continued until
active haemorrhage is stopped and until the treated area is blackened and cavitated.
36
Table 1.13 Heater probe for gastrointestinal bleeding
Study Group Re-bleed (%) Surgery (%) Mortality (%)
Fullarton, 1989
HP (n = 20) 0(0) 0(0) 0(0)
Sham (n = 23) 5(22)* 3(13)** 0(0)
Jensen, 1988
BICAP 44 33 3
HP 22 *** 2 *** 3
Nil 72 41 9
n (total) = 94
Jaramillo, 1993
HP (n = 51) 5(10) 3(6) 0(0)













Monopolar electrocoagulation uses a metal ball-tipped probe. An electrical circuit is
completed by a plate attached to the patient. Application of energy is rather
haphazard and perforations and a death were reported in early series. Consequently
this device is no longer used. Bipolar electrocoagulation is based upon transmission
of electrical energy between adjacent electrodes. The BICAP has eight separate
electrodes over its surface. Early studies from the United Kingdom involving small
numbers of patients showed no benefit for active treatment compared to conservative
therapy. Subsequently however, trials from the United Kingdom and the USA
showed that primary haemostasis, re-bleeding, the need for surgery and transfusion
requirements were all improved by bipolar electrocoagulation compared to
conventionally treated patients (O'Brien et al., 1986; Laine, 1987; Brearly et al.,
1987; Laine, 1988) (Table 1.14). The efficacy of the heater probe and BICAP are
comparable and the two modalities have similar low complication rates (Wong et al.,
2002; Papp, 1987).
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Bipolar probe 101 17(17)* 7(7) 4.6 **
Nil 103 34 (33) 10(10) 7.3
aLaine, 1987
MPEC 21 3(14)*** 2.4 t
Sham 23 10(43) 5.4
Brearley, 1987
Bipolar probe 20 6(30)
Nil 21 8 (38)
bLaine, 1988
MPEC 37 7(19)| 3(8) 1.6 %






t p = 0.002.
i p < 0.05.
MPEC, multipolar electrocoagulation.
aStudy included ulcers, Mallory-Weiss tears, and vascular malformations.
bStudy was restricted to ulcers with non-bleeding visible vessels. See also Jensen,
1988 Table 1.13
ARGON PLASMA COAGULATION
This procedure is based upon coagulation through a jet of argon gas. Relatively
superficial thermal damage is achieved. The method is particularly applicable to
mucosal and superficial bleeding lesions, and its final role may be in dealing with
vascular malformations such as gastric antral vascular ectasia. One small trial has
shown that argon plasma coagulation is comparable in efficacy to heater probe
therapy for ulcer haemostasis (Cipolletta et al., 1998). A second trial compared the
argon plasma coagulator with combination injection of adrenaline and polidocanol
(Skok et al., 2001). Again the two approaches were equally effective. Nevertheless
the tissue damage characteristics of argon plasma coagulation are less than ideal for
managing arterial bleeding, and it will probably prove to be less appropriate for
managing peptic ulcer bleeding than contact methods.
CONCLUSIONS
Thermal methods of haemostasis were shown to be superior to conservative
management in two meta-analyses. In a meta-analysis, involving thermal contact
devices, laser and injection therapy performed by Cook et al. (1992) the odds ratio
for prevention of re-bleeding was 0.48 (95% CI 0.32-0.76); and for avoidance of
surgery was 0.47 (95% CI 0.27-0.80). Similarly, in the study of Henry and White
(1988), the odds ratio for prevention of bleeding was 0.32 (95% CI 0.22-0.41) and
for the avoidance of surgery was 0.31 (95% CI 0.19-0.43). Thermal contact methods
(heater probe and bipolar coagulation) are technically easier to undertake than laser
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techniques. There are insufficient data to determine whether the heater probe is better
than the BICAP.
The safety profile of thermal modalities is generally very good. Perforations are
unusual and treatment induced exacerbation of bleeding is not usually clinically
important.
Injection therapy
Injection treatment is simple to perform and is the cheapest available haemostatic
modality. A number of injection materials have been studied and it is difficult to
prove that any one of these is superior to others.
DILUTE ADRENALINE
In 1988 Chung et al. reported a controlled trial in which patients with active ulcer
bleeding were randomised to receive endoscopic injection with 1:10,000 adrenaline
or to conservative treatment. Primary haemostasis was achieved in all injected
patients and the need for subsequent urgent surgery was significantly reduced (Table
1.15). Re-bleeding occurred in 24% of injected patients, suggesting that although
dilute adrenaline did stop active bleeding, its effects were temporary.
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Table 1.15 Adrenaline for gastrointestinal bleeding
Outcome Adrenaline (n = 34) Conservative (n = 34)
Primary haemostasis (%) 34(100)
a
Surgery (%) 5(15) 14(41)
Mortality (%) 3(9) 2(6)
20 patients stopped bleeding spontaneously.
Source: Chung et al., 1988
It seemed logical to combine an injection of adrenaline with that of an agent which
might cause permanent sealing of the bleeding arterial defect. For this reason a series
of trials were undertaken in which adrenaline injection was combined with a range of
sclerosants.
The results of trials in which a combination of adrenaline plus sclerosants were
compared to conservative therapy are summarised in Table 1.16 (Panes et al., 1987;
Rajgopal and Palmer, 1991; Balanzo et al., 1988; Oxner et al., 1992). All showed
that active bleeding stopped more rapidly in treated patients, that re-bleeding rates
were less and that the need for a surgical operation was reduced. No single trial,
however, was powerful enough to determine whether mortality was affected. The
meta-analysis by Cook et al. (1992) did show a modest reduction in mortality,
although this only achieved statistical significance for laser therapy.
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Surgery (%) Mortality (%)
Panes, 1987
Adr + Pol + Cim 55 3(5) 3(5) 2(4)
Cim 58 25(43) 20 (34) 4(7)
Rajgopal, 1991
Adr + Eth 56 7(13) 6(11) 2(4)
Nil 53 25 (47) 13 (25) 3(6)
Balanzo, 1988
Adr + Pol 36 7(19) 7(19)
Nil 36 15 (42) 15 (42)
Oxner, 1992
Adr + Eth 48 8(17) 4(8) 4(8)
Nil 45 21 (47) 8(18) 9(20)
Adr, adrenaline; Pol, polidocanol; Eth, ethanolamine; Cim, cimetidine.
SCLEROSANTS
The sclerosants that have been studied are polidocanol, 5% ethanolamine oleate, and
3% sodium tetradecyl sulphate. There are no controlled trials in which outcome has
been assessed in patients randomised to sclerosant injection versus conservative
therapy. Several trials compared the efficacy of sclerosants with other endoscopic
therapies. Benedetti et al. (1990) showed similar efficacy for polidocanol and
thrombin injection in patients presenting with a range of bleeding lesions. Strohm et
al. (1994) randomised patients to one of four treatment arms (fibrin glue, 1%
polidocanol, dilute adrenaline or adrenaline plus polidocanol) and showed no
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advantage for any one approach. Rutgeerts et al. (1989) showed no difference in
outcome for patients treated by polidocanol or Nd-YAG laser therapy. In general
these studies suffer from the problem of small sample size, and they probably lacked
statistical power.
A series of case reports have documented complications of injection by sclerosant
(Levy et al., 1991; Loperfido et al., 1990), particularly perforation and necrosis of the
upper gastrointestinal tract. These complications did not occur following adrenaline
injection and indeed the latter seems remarkably safe. Fears concerning the possible
systemic affects of circulating adrenaline have not translated into cardiovascular
mishaps. Since complications are mainly due to sclerosant injection, it was important
to confirm the importance of combining the sclerosant with the adrenaline injection.
Whilst the logic of attempting to induce endarteritis using sclerosants was
reasonable, experiments in animals did not demonstrate that this could be achieved
by injection using ethanolamine or absolute alcohol (Rajgopal et al., 1992). Three
trials compared the efficacy of injection by adrenaline alone versus a combination of
adrenaline plus a sclerosant (Villanueva et al., 1993; Choudari and Palmer, 1994;
Chung et al., 1996). As shown in Table 1.17, these three studies did not show that
combination treatment was superior to injection by adrenaline alone. No study has
directly compared outcome in patients randomised to dilute adrenaline or to a
sclerosant. Since the addition of sclerosants to an injection of adrenaline offers no
proven advantage over injecting adrenaline alone, and because sclerosants have the
potential to cause significant local complications following injection, they should no
longer be employed as part of the injection treatment regimen.
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ALCOHOL
The efficacy of injecting absolute alcohol into bleeding ulcers has been examined in
several clinical trials. Two of these (Pascu et al., 1989; Lazo et ah, 1992) (Table
1.18) randomised patients to alcohol injection or to conservative therapy and showed
benefit in terms of reduction in re-bleeding rates and need for surgical intervention.
Table 1.18 Alcohol vs conservative therapy for gastrointestinal bleeding
Study Group n Re-bleeding (%) Surgery (%) Mortality (%)
Pascu, 1989
Alcohol 65 1 (2) * 1 (2)* 2(3)
Conservative 78 17(22) 17(22) 10(13)
Lazo, 1992
Alcohol 25 2(8) ** 1 ^4) ***





In a prospective randomised comparative trial, Lin et ah (1993) reported that alcohol
injection stopped active bleeding and prevented re-bleeding in 86% of patients whose
ulcers were injected, and this result was similar to the proportion of bleeding ulcers
responding to injection with 3% sodium chloride, 50% dextrose, or normal saline.
Only one small study (Chiozzini et ah, 1989) has attempted to compare the efficacy
of alcohol with dilute adrenaline injection but this lacked statistical power to
demonstrate possible differences in the efficacy of these interventions.
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The evidence that alcohol stops active bleeding and prevents re-bleeding is stronger
than that for the sclerosants. Unfortunately, the potential for adverse effects is
probably higher for alcohol than for adrenaline. Deep ulcers commonly follow
alcohol injection and perforations have occurred (Nakagawa et al., 1989).
Whilst alcohol injection is an effective haemostatic therapy, current evidence
suggests that the magnitude of its effect is probably similar to that achieved by
injection with adrenaline alone. Because of its propensity for causing adverse effects,
alcohol injection is not recommended as treatment for ulcer bleeding.
FIBRIN GLUE AND THROMBIN
The most attractive endoscopic approach is to directly cause blood clot formation by
injecting thrombogenic substances. In the 1980s small trials examined the efficacy of
bovine thrombin and showed little benefit compared to other modalities.
In 1996 Kubba et al. reported a comparison of endoscopic injection therapy using a
combination of adrenaline plus human thrombin with dilute adrenaline injection
alone (Table 1.19). A proportion of randomised patients had active bleeding at the
time of randomization, while the remainder had non-bleeding visible vessels. Re-
bleeding and mortality were significantly reduced in the group receiving combination
therapy compared to patients receiving adrenaline alone. The number of patients
needed to be treated with combination therapy rather than adrenaline alone to prevent
one death is approximately 14. Paradoxically, no statistically significant differences
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in the need for surgical operation and the overall rate of haemostasis were
demonstrated. Indeed, deaths in this study all occurred, as is usually the case, in
patients who had significant co-morbidity. There were no complications. Although
this was not a direct comparison of adrenaline versus thrombin, it did strongly
suggest that human thrombin is an effective modality.







Re-bleed (%) 3(4) 14 (20) *
Transfusion (units) 7 5
Surgery (%) 3(4) 5(7)
Mortality (%) 0(0) 7(10) **
* p< 0.005.
** p<0.013.
Source: Kubba et al., 1996
In a large multicenter European study (Rutgeerts et ah, 1997) (Table 1.20) 850
patients were randomised to endoscopic injection with dilute adrenaline plus a single
injection of fibrin glue, to adrenaline and repeated injection of fibrin glue given at
daily intervals according to the discretion of the endoscopists, or to adrenaline plus
1% polidocanol. Fibrin glue is a mixture of fibrinogen and thrombin which is
injected through a double-channeled endoscopy needle. Re-bleeding rates were
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lowest in patients treated by repeated injection, and serious re-bleeding requiring
major blood transfusion or surgical operation, was significantly reduced in patients
receiving repeated injections of glue compared to the polidocanol treated group. A
total of seven perforations occurred in this study and these were distributed equally
amongst the treated modalities.
Table 1.20 Adrenaline plus fibrin glue vs adrenaline plus polidocanol for
gastrointestinal bleeding
Outcome
Adr + rep FG
(n = 284)




Re-bleed (%) 41 (16) 51 (19) 58 (21) *
Transfusion (units) 3.7 3.2 3.3
Surgery (%) 9(3) 13(5) 13(5)
Perforation (%) 2(1) 2(1) 3(1)
30-day mortality (%) 12(4) 15(5) 13(5)
* p< 0.036.
Adr, adrenaline; FG, fibrin glue; Pol, polidocanol.
Source: Rutgeerts et al., 1997
Finally, a small study (Heldwein et ah, 1996) which compared a combination of
adrenaline plus fibrin glue with adrenaline plus Nd-YAG laser therapy did not show
a difference in outcome, but this study lacked sufficient statistical power.
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Although no direct comparisons have been made of injection therapy using thrombin
alone versus other single agents, the impression gained from the trial evidence is that
the use of thrombogenic agents confers significant benefit in terms of the usual
endpoints. Acute complications occur infrequently. Although thrombin has been
derived from pooled plasma, viral transmission has not been reported. Furthermore,
no adverse effects have been apparent in terms of systemic coagulation.
Human thrombin is not currently commercially available. It is relatively inexpensive
at £35 per vial, although more costly than adrenaline at £1 per vial.
CONCLUSION
Injection therapy is effective and safe. The optimum injection regimen should
probably include dilute adrenaline, which stops active haemorrhage. Re-bleeding
rates may be reduced by the addition of agents such as thrombin or a thrombin-
fibrinogen mixture. Sclerosants and alcohol should not be used since there is no
evidence that they are beneficial and they increase the risk of serious complications.
Comparison of injection and thermal treatments
A number of small trials have compared injection with thermal therapies, and as in
most studies in this field, numbers are small. In general, the two modalities appear to
have equivalent efficacy.
50
Six trials have compared heater probe with injection (Lin et ah, 1988; Lin et ah,
1990; Chung et ah, 1991; Choudari et ah, 1992; Saeed et ah, 1993; Llach et ah,
1996) (Table 1.21). The two trials reported by Lin et ah (1988, 1990) showed that
heater probe treatment was more effective in achieving primary haemostasis. These
authors noted the heater probe to be better when ulcers were difficult to approach, as
it can be applied tangentially. They also found the water jet to be useful in spurting
bleeding. It may be argued that alcohol is a less appropriate injection therapy than
adrenaline, which may account for the apparent superiority of the heater probe in
these studies. This view was supported by the findings of Chung et ah (1991). They
concluded that heater probe and adrenaline were equally effective, but that initial
haemostasis was more easily achieved with adrenaline. Choudari et ah (1992)
compared the heater probe with adrenaline plus ethanolamine and found no
differences between the modalities. The remaining two trials by Saeed et ah (1993)
and Llach et ah (1996) support this conclusion. Laine (1990) showed that
electrocoagulation and injection with ethanol were equivalent, although the size of
this trial was suboptimal.
Two trials involved the Nd-YAG laser. Carter et ah (1994) compared laser with
adrenaline and Pulanic et ah (1995) in a much larger trial, compared laser with
polidocanol. Neither showed a difference in outcome.
Current evidence does not allow a conclusion to be drawn on whether injection or
thermal treatment is superior.
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HP 42 42(100) 5(12)
PA 36 29 (81) 6(22)
Lin, 1990
HP 45 44 (98) * 8(18) 3(7) ** l(2)f
PA 46 31 (67) 2(7) 2(4) 0
Control 46 12(26) 7(15)
Chung, 1991
HP 64 53 (83)% 6(11) 14(22) 4(6)
Adr 68 65 (96) 11(17) 14(21) 2(3)
Choudari,
1992
HP 60 9(15) 7(12) 3(5)
Adr + Eth 60 8(13) 7(12) 2(3)
Saeed, 1993
HP 39 35 (90) 4(10)
Ethanol 41 33 (81) 5(12)
Llach, 1996
HP 53 3(6) 2(4) 1 (2)




p = 0.0024 (p = 0.027 between control and HP; p = 0.012 between PA and HP),
t p = 0.002 (p = 0.031 between control and HP; p = 0.018 between control and PA).
t p < 0.05.
HP, heater probe; PA, pure alcohol; Adr, adrenaline; Eth, ethanolamine; Pol,
polidocanol.
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Combination of injection and thermal treatments
The mechanisms leading to haemostasis associated with thermal treatment and
injection therapy may differ, providing a rationale for combining a thermal modality
with injection treatment. Currently, only one small study has shown overall benefit
from use of such a combination. This trial by Lin et al. (1999) used the gold probe, a
bipolar coagulation probe containing an injection needle in the centre. Using this
device heat and injection therapy may be applied without removing the probe from
the ulcer. Ninety six patients were included in this randomised trial, injection alone,
coagulation alone or combination therapy being applied to 32 patients each. Re-
bleeding rates were lower in the combination group compared to the injection alone
and coagulation alone groups (7% vs 36%, p=0.01 and 7% vs 30%, p=0.04
respectively), and volume of blood transfused in the combination group was
significantly lower. Although this trial indicates a beneficial outcome following
combination endoscopic therapy, the number of patients in each group was small,
this limiting the impact of the conclusion. A much larger trial is required.
A further encouraging trend relates to a finding within a study reported by Chung et
al. (1997) This study involved randomization of appropriate ulcer bleeding patients
to injection therapy using 1: 10,000 adrenaline or to a combination of adrenaline plus
the heater probe (Table 1.22). Although there was no overall difference in outcome
between patients randomised to either arm, a post hoc subgroup analysis did reveal
positive findings. Sixty patients had active spurting haemorrhage from large ulcers,
and within this group the primary haemostatic effect of both treatments was similar.
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However, the need for operation was significantly reduced in the group treated by
heater probe and injection. The number of endpoints was small and this observation
from subgroup analysis requires confirmation in further trials.








Primary haemostasis (%) 135 (99) 131 (98)
Re-bleed (%) 5(4) 12(9)
Transfusion (units) 3 2
Surgery (%) 8(6) 14(11)
Mortality (%) 8(6) 7(5)
Subgroup with spurting haemorrhage
n 32 28
Primary haemostasis (%) 31 (97) 25 (89)
Re-bleed (%) 2(6) 6(21)
Transfusion (units) 4 5
Surgery (%) 2(6) 8(29)*
Mortality (%) Not stated Not stated
*
p = 0.03.
Source: Chung et al., 1997
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Mechanical clips
The haemoclip was first used for non-variceal bleeding by Japanese investigators in
the early 1970's (Hayashi et al., 1975). The device has gained favour, particularly in
Japan, and is the endoscopic method most analogous to under-running an ulcer at
operative surgery. Three large case series (Binmoeller et al., 1993; Yokohata et al.,
1996; Nagayama et al., 1999) support haemoclips as a safe and effective method for
the treatment of bleeding peptic ulcer and there are five prospective randomised trials
of reasonable size (Chung et al., 1999; Cipoletta et al., 2001; Lin et al., 2002; Lin et
al., 2003; Gevers et al., 2002).
Chung IK et al. published a prospective randomised trial comparing haemoclips with
adrenaline injection in 1999. One hundred and twenty four patients with actively
bleeding ulcers or ulcers with vessels were included. Forty one patients were treated
with haemoclips, 41 with adrenaline and 42 with a combination of the two. Re-
bleeding occurred in 2.4%, 14.6% and 9.5% respectively. Three patients had
complications, all in the adrenaline group.
Cipoletta et al. (2001) randomised 113 patients with endoscopic stigmata of
haemorrhage to heater probe thermocoagulation or to application of haemoclips. A
mean of three clips per patient were used with up to six being required in some cases.
Re-bleeding was dramatically reduced in the haemoclip group with rates in the clip
and heater probe groups of 1.8 % and 21 % respectively. There were no
complications.
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The two previous trials suggested clips to be effective, with re-bleed rates below 3%
in the clip only groups. Three subsequent studies however have been less
encouraging. Eighty patients were randomised to heater probe thermocoagulation or
to placement of haemoclips in the trial by Lin et al. (2002). Primary haemostasis was
achieved in only 85% of patients in the clip group versus 100% of those treated with
the heater probe. Re-bleed, surgery and mortality rates were no different.
Subsequently, Lin et al. (2003) compared 46 ulcer bleeding patients treated by
haemoclip placement with 47 patients in whom heater probe thermocoagulation and
adrenaline injection were used. The rate of primary haemostasis was lower in the
haemoclip group (95.1% vs 100%, p>0.1). Re-bleeding, surgery and mortality rates
were equivalent. Gevers et al. (2002) performed a similar trial to Chung et al. (1999)
in which 101 patients were randomised to injection with adrenaline and polidocanol,
haemoclip application or a combination of the two. The overall failure rate was
significantly higher in the haemoclip alone group when compared with the injection
and combination groups (34%, 6% and 25% respectively, p=0.01).
The major difficulty with haemoclip placement occurs when ulcers are difficult to
reach and tangential application is required. Initial clip applicators resulted in
problems with clip alignment, but a rotary applicator has now been developed.
Further problems arise when clips are applied to the fibrous base of a chronic ulcer,
as in this situation it may not be possible to adequately compress the bleeding vessel.
In the trial by Lin et al. (2002) a surveillance endoscopy was performed at 72 hours
following therapy. Haemoclips had been successfully placed in 31 patients, but at 72
hours the clip was still attached to the ulcer base in only 10 patients. This could have
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accounted for the disappointing performance of the clip group, and perhaps clips
with a more powerful clamping mechanism would improve the efficacy of the
device. Further trials with improved clips are required.
Endoscopic therapy for ulcers with adherent blood clot
There is debate concerning what should be done with blood clot which is tightly
adherent to an ulcer base. It is possible to deliver endoscopic therapy around the base
of, and through an adherent clot. The efficacy of this approach is not known. To
remove a clot seems counter-intuitive in the situation of acute bleeding, but to leave
it in situ prevents accurate categorisation of stigmata of haemorrhage, and may
prevent correct application of endoscopic therapy. Lin et al. (1996) showed that when
clot is tightly adherent after washing for 10 seconds with Water Pik irrigation, the re-
bleed rate is 25%. Factors independently associated with re-bleeding in this situation
were the presence of shock, co-morbid disease and haemoglobin less than 10 g/dl.
Bleau et al. (2002) published a small trial in which patients with adherent clot were
randomised to pre-injection with adrenaline followed by clot removal and
thermocoagulation of a visible vessel (n=21), or to medical therapy (n=35). The
patients in the endoscopic therapy group had a significantly lower re-bleeding rate
(5%) compared with those in the medical therapy only group (34%), although the
numbers were small. A similar but very small trial (32 patients) has been reported by
Jensen et al. (2002). The results were similar, with re-bleeding rates of 0% in the clot
removal and endoscopic therapy group versus 35% for those treated with medical
therapy only. These trials suggest that clot removal and therapy to the underlying
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stigmata is a safe and effective strategy. A further trial should now randomize
patients to clot removal and endoscopic therapy, or to endoscopic therapy delivered
through the clot.
Elective repeat endoscopic therapy
It is not yet clear whether electively repeating endoscopy and haemostatic therapy in
the absence of clinical or endoscopic signs of re-bleeding is a useful strategy. There
are six trials which include patients receiving repeated endoscopic therapy (Rutgeerts
et al., 1997; Pescatore et al., 2002; Messman et al., 1998; Villanueva et al., 1994;
Saeed et al., 1996; Chiu et al., 2003) and four of these have specifically addressed the
question of the efficacy of endoscopic re-treatment (Messman et al., 1998;
Villanueva et al., 1994; Saeed et al., 1996; Chiu et al., 2003). The trial by Pescatore
et al. (2002) reported no clear benefit from the use of an elective repeat endoscopy
approach. A similar conclusion was reached by Messmann et al. (1998) in a study of
105 patients who had required endoscopic therapy for bleeding ulcers. Patients were
randomised to daily repeat endoscopy with re-treatment of persistent stigmata, or to
close observation. There was no difference between the groups for any of the usual
end-points. In contrast to these results, Rutgeerts et al. (1997) reported a clear
positive trend towards reduction in re-bleeding in patients treated with programmed
repeat endoscopic therapy. Villanueva et al. (1994) randomised 104 patients in whom
endoscopic haemostasis had been achieved following injection of adrenaline, to
repeat endoscopy or to observation. There were trends towards a better outcome in
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the repeat endoscopy group but statistically significant reductions in re-bleeding,
surgery and mortality were not demonstrated.
There are two trials suggesting that repeat endoscopic therapy significantly reduces
re-bleeding rates. The very small trial by Saeed et al. (1996) included only 40
patients, but Chiu et al. (2003) randomised 194 patients following endoscopic
haemostasis using adrenaline injection and heater probe thermocoagulation. One
hundred patients underwent a scheduled repeat endoscopy and 35 of these required
further endoscopic therapy. The remaining 94 patients were observed closely. All
patients received intravenous omeprazole 40mg twice daily for 72 hours following
endoscopy. The mean total volume of adrenaline injected in the repeat endoscopy
group was 11.1ml compared with 9.1ml in the control group (p=0.008). The mean
total joules of heater probe therapy in the two groups were 95.3 and 110.2
respectively. Re-bleeding rates were significantly lower in the repeat endoscopy
group compared to the control group (5% vs 14%, p=0.034). There was also a trend
towards reduction in the requirement for surgery (1% vs 6%, p=0.05). Mortality rates
were similar in the two groups.
Two meta-analyses examining the above trials have been published (Marmo et al.,
2003; Chiu et al., 2003). Both suggest that elective repeat endoscopy significantly
reduces re-bleeding, but has no beneficial effect on the rates of surgery or mortality.
Potential complications of repeat endoscopic therapy including sedation related
cardiorespiratory adverse events, and heater probe related perforation have not been
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reported. In many cases repeat endoscopic therapy is not required at the time of
second look endoscopy, and a cost-benefit analysis of a policy of elective repeat
endoscopic therapy would be desirable. Currently, the total number of patients
studied is small, but the available evidence indicates that elective repeat endoscopic
therapy may be beneficial in patients at high-risk of re-bleeding or surgery. Repeat
endoscopy should also be considered in cases where the endoscopist is not convinced
that adequate haemostasis has been achieved at the time of the initial endoscopy.
Failure of endoscopic therapy
It may be argued that endoscopists can adversely affect outcome in patients who fail
endoscopic therapy. Repeated unsuccessful therapeutic endoscopy, large blood
transfusion, and delayed surgical operation in those who ultimately fail attempted
endoscopic haemostasis all increase the risk of death. Unfortunately, we cannot
predict who will fail and who will respond to endoscopic therapy. Seven analyses
(Villanueva et al., 1993; Choudari et al., 1994; Hsu et al., 1994; Brullet et al., 1996
(Gut); Brullet et al., 1996 (Gastrointest Endosc); Chung IK et al., 2001; Wong et al.,
2002) have shown that the presence of active bleeding, large ulcer size, an ulcer
situated in the posterior duodenum, the presence of significant co-morbid disease,
shock and a haemoglobin less than lOg/dl are factors associated with failures of
therapy. However, even in the highest risk group of patients, who present with active
spurting haemorrhage from large posterior duodenal ulcers, endoscopic haemostasis
can be achieved in approximately 70% of patients (Choudari et al., 1994). Currently
it is not possible to accurately define the subgroup of patients in whom endoscopic
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therapy should not be attempted. What is clear is that patients who have actively
bleeding, large posterior duodenal ulcers are at very high-risk of requiring urgent
operation.
Policy concerning re-bleeding after failed endoscopic therapy has been examined by
Lau et al. (1999). Of 3473 patients admitted with bleeding peptic ulcers, 1169
underwent endoscopic therapy in an attempt to achieve haemostasis. Primary
haemostasis was achieved in a remarkable 98.5% of patients. One hundred of these
re-bled after endoscopic therapy and 92 were randomised to endoscopic re-treatment
or to emergency surgery. The characteristics of the two groups of patients were
similar, including the median transfusion requirements before randomization.
Endoscopic re-treatment consisted of a combination of adrenaline injection plus the
heater probe. Overall, more complications occurred in the group randomised to
surgery and there was no significant difference in 30-day mortality between the two
groups (Table 1.23). This paper suggests that endoscopic re-treatment rather than
immediate, urgent operative surgery should be considered in patients who re-bleed
after endoscopic haemostatic therapy.
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Table 1.23 Repeat endoscopic therapy vs surgery for patients who re-bleed
Outcome Endoscopic therapy Surgery
n 48 44
Transfusion (units) 8 7
Complications (no. ofpts) (%) 7(15) 16 (36) *
Mortality (30-day) (%) 5(10) 8(18)
*
p = 0.03.
Source: Lau et al. (1999)
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Endoscopic therapy: summary
Endoscopic therapy for non-variceal haemorrhage is safe and effective, and should
be used in the 20% of patients who have major endoscopic stigmata of recent
haemorrhage. Combination therapy may produce the best results, but there is no
definitive proof that this is the case. It is possible that combination therapy is the best
approach for patients with active, spurting haemorrhage. Thermal haemostasis is
effective using either the heat probe or multipolar electrocoagulation. No injection
agent has been convincingly shown to be superior to dilute adrenaline solution.
Injection of larger volumes may improve outcome. The haemoclip requires further
development. Re-bleeding should be treated first by further endoscopic intervention,
although clinical judgment should dictate when urgent surgery is required for
specific high-risk cases.
Intravenous infusion of proton pump inhibitor drugs is recommended following




A randomised controlled trial comparing heater probe
plus thrombin with heater probe plus placebo for
bleeding peptic ulcer: Patients and Methods
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Introduction
This thesis is based upon a clinical trial which examined the hypothesis that
combination injection and heater probe therapy is superior to heater probe therapy
alone in preventing re-bleeding after major peptic ulcer haemorrhage. A previous
clinical trial showed that injection of human thrombin into the bleeding ulcer is a
highly effective haemostatic treatment (Kubba et al., 1996), and others have also
shown that injection of agents which lead to blood clot formation improves outcome
in these patients (Rutgeerts et ah, 1997). Thrombin was therefore used as an injection
material, combining this with the heater probe.
No previous clinical trials of endoscopic therapy had been placebo controlled and
many studies are therefore open to criticism. In this double blind study patients were
randomised to receive either a combination of heater probe plus thrombin injection
or heater probe plus placebo injection.
Patients
Patients were recruited from four Scottish regions between November 1996 and
January 2001. The participating centres were as follows:
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1. Edinburgh (Western General Hospital, Royal Infirmary, St. John's Hospital)
2. Aberdeen (Aberdeen Royal Infirmary)
3. Dundee (Ninewells Hospital)
4. Glasgow (Gartnavel General Hospital)
All patients presenting with significant haematemesis and/or melaena were
considered for inclusion into the trial. All had peptic ulcers with major endoscopic
stigmata comprising active bleeding or a non-bleeding visible vessel. At endoscopy
the bleeding point was vigorously washed to remove adherent clot and facilitate full
endoscopic visualisation. In 20 cases blood clot was initially adherent. In all of these,
snares and washing catheters were used to reveal a non-bleeding visible vessel in 19
and active, spurting haemorrhage in one. In order to be eligible for inclusion into the
study at least one additional clinical risk factor from age over 60 years, haemoglobin
less than 10 g/dl, the presence of shock (defined as a pulse rate greater than 100 beats
per minute or a systolic blood pressure less than 100 mmHg or both) and significant
co-morbid disease was necessary. Co-morbid disease was classified and graded as
shown in Table 2.1. Arbitrary scores of 1 to 3 were applied to disease in major organ
systems depending on the disease severity, and the sum of the scores for each
category produced the final co-morbid disease score for each patient. Rockall scores
(Rockall et al., 1996) were calculated for all patients (see Chapter 1).
Exclusion criteria comprised the use of anticoagulant drugs, the presence of a
coagulopathy, known severe chronic liver disease, advanced malignancy, a history of
severe reactions to blood products and pregnancy.
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Table 2.1 Classification of co-morbid disease
Category Score
Liver/Gastrointestinal
Inactive or mild liver disease, inactive inflammatory bowel disease (IBD) 1
Cirrhosis/portal hypertension, moderate IBD, short bowel syndrome, chronic
pancreatitis
2
Liver failure, encephalopathy, severe active IBD, acute pancreatitis 3
Cardiovascular
Stable angina, previous myocardial infarction (MI), hypertension, mild
peripheral vascular disease (PVD)
1
Bad angina, mild congestive cardiac failure, valvular heart disease, moderate
PVD
2
Recent MI (within 4 weeks), severe heart failure, severe PVD 3
Respiratory
Mild asthma/ chronic obstructive airways disease (COAD) 1
Asthma/COAD chronic but no exacerbation, chest infection, pulmonary embolus
at least 2 months previously
2
Respiratory failure, recent PE, pneumonia, severe exacerbation of asthma/COAD 3
Diabetes
Well controlled diabetes 1
Diabetic with complications 2
Ketoacidosis 3
Arthritis
Minor conditions including mild rheumatoid arthritis (RA), gout, symptomatic
osteoarthrosis
1
Less severe RA but requiring medication 2
Severe RA, connective tissue disease 3
Neurological
Previous stroke, Parkinson's disease receiving treatment, other chronic
neurological disease
1
Stoke within 6 months with residual disability, recent transient ischaemic
episode, severe dementia
2
Stroke within 4 weeks, severe neurological condition with disability 3
Renal
Mild renal failure/impairment, mild renal disease 1
Chronic renal failure, chronic renal disease 2
Acute renal failure, dialysis, transplant 3
Cancer
Early/mild (e.g. prostatic/cervical/bladder), chronic leukaemias and non-
malignant tumors
1
Limited spread or treated cancer 2
Terminal cancer, disseminated cancer, acute leukemia 3
Recent operation (within 4 weeks) or trauma
Minor operations, minor burns/trauma 1
Recent major operation, severe burns/trauma 3
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Randomisation
Written consent was obtained, either from the patient or in some cases from a close
relative, prior to endoscopy. Endoscopy was undertaken following resuscitation, and
patients found to have peptic ulcers with appropriate stigmata of haemorrhage were
entered into the trial. All patients were treated with the heater probe followed by
injection of trial material, which was contained in consecutively numbered boxes.
These were allocated using randomised permuted blocks of length ten to contain
vials of human thrombin or matching placebo. Allocation was concealed and the trial
investigators were blinded to the contents of the vials of trial injection material.
Endoscopic Therapy
Endoscopy was carried out using Olympus forward viewing gastroscopes (Q200,
XQ240, XQ10, XQ20 or 2T200). All procedures were carried out by myself or by
senior endoscopists experienced in the use of the heater probe and injection therapy.
The Olympus heater probe unit (HPU/HPU 20) with 2.4mm or 3.2mm diameter
probes (CD20Z, CD10Z, CD120U, CD110U) was used. All probes were calibrated
by the manufacturer to produce the same heating characteristics. Firm tamponade
was applied before application of 20 to 30J pulses. The probe was applied
circumferentially around non-bleeding vessels and then to the vessel itself. Two to
four pulses were delivered at each position. Application was continued until active
bleeding (if present) stopped and the bleeding point was blackened and cavitated.
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Injection was carried out using a disposable 4mm injection needle (Keymed Ltd,
Southend upon Sea, UK). Human thrombin 1000 iu or placebo was presented in
apparently identical vials of dry powder. The powder was reconstituted with sterile
water, producing a 3.5 - 4ml injection volume after priming the injection needle. This
was injected in 1ml aliquots into the bleeding point following application of the
heater probe.
Each box contained two vials to allow for a second injection should this prove
necessary in the event of re-bleeding.
THROMBIN
Human thrombin was produced by the Scottish National Blood Transfusion Service
(SNBTS) and was initially derived from cryoprecipitate obtained from voluntary UK
blood donations. When the new-variant Creutzfeldt Jacob Disease crisis developed in
the UK in 1997, human thrombin derived from UK donors was withdrawn due to the
possibility of transmission of the disease by plasma products. Thereafter thrombin
was fractionated in an identical manner from plasma donated in the USA and
Germany. The extract was subjected to two virus inactivation steps comprising an in-
process solvent/detergent step using 1% Tween 80 and 0.3% Tri N Butyl Phosphate
at 25°C for at least 6 hours, followed by dry terminal heat treatment at 80°C for 72
hours. This has been shown to inactivate a range of enveloped and non-enveloped
viruses (Bennet et al., 1993; Horowitz et al., 1993; Rizza et ah, 1993). Despite the
virus inactivation steps in the manufacturing process thrombin injection carries a
theoretical risk of transmission of Parvovirus B19 and Hepatitis A. In order to
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monitor the safety of thrombin injection, 10ml clotted samples of blood were taken
from all patients prior to endoscopy and six months after injection. These samples
were analysed for antibodies to Parvovirus B19 and Hepatitis A to monitor for
seroconversion. As part of the SNBTS standard safety procedures, post-endoscopy
samples were tested for Hepatitis B and Hepatitis C antibodies and Hepatitis B
surface antigen. In the event of positive post-endoscopy tests for hepatitis B or C, the
pre-endoscopy samples were tested. This approach avoided testing the entire patient
group for hepatitis B and C.
PLACEBO
Matching placebo was produced by the Protein Fractionation Center in Edinburgh.
Each vial contained all the constituents of the SNBTS thrombin concentrate except
for thrombin itself, which was replaced by human albumin. Specifically this
comprised an isotonic solution containing sodium citrate, sodium chloride, sodium
gluconate and 1,9g/l human albumin. The appearance and viscosity of the active and
placebo solutions were identical, and none of these constituents are known to have
vasoconstrictor activity.
Follow Up
Following endoscopy patients received proton pump inhibitor drugs and, if
appropriate H. Pylori was eradicated by a seven-day course of antibiotics combined
with a proton pump inhibitor drug. Following endoscopic therapy clinical
management decisions were left to the admitting physicians or surgeons at the
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respective units. Endoscopy was only repeated during the admission if re-bleeding
was suspected.
The primary end point of the trial was:
Re-bleeding, defined as the passage of fresh haematemesis or melaena associated
with the development of shock or a fall in haemoglobin concentration by at least 2
g/dl in 24 hours. This was diagnosed by clinicians who were in charge of all
management decisions but had no knowledge of whether patients had received
thrombin or placebo.
Secondary end points were:
1. Need for urgent surgery to prevent exsanguination. The decision to undertake
surgery was made by the parent unit on the basis of the clinical condition of
the patient.
2. 30-day mortality.
3. Volume of blood transfused.
4. Duration of hospital admission.
Re-bleeding was confirmed whenever possible by further endoscopy. If major
stigmata were found, heater probe application and injection of the second vial of
reconstituted test material were undertaken. Surgery was performed if active
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bleeding could not be controlled or when further gastrointestinal haemorrhage
occurred.
Patients were followed up by out-patient review or telephone call 30-days after the
initial bleed. All patients were contacted six months after injection and in those who
consented repeat blood samples were taken to ensure no virus transmission had
occurred.
Statistical Design
The trial was designed to have an 80% power to detect a difference between re-
bleeding rates of 5% and 16% at the 5% level of significance. It was assumed that
approximately 16% of patients would re-bleed after heater probe plus placebo, based
upon previous published trials (Choudari et al., 1992; Lin et ah, 1990; Chung et ah,
1991). It was calculated that 120 patients would be required in each arm. Differences
in proportions were analyzed using the y2 test with Yates' correction. Length of
hospital stay was compared using the t-test after logarithmic transformation. Blood
transfusion requirements were compared using the Wilcoxon Rank Sum Test. In
order to monitor the safety of the trial for participants, the mortality rates were
compared at intervals of approximately 75 patients and it was predetermined that the
data would be examined in detail if differences were significant at a level of 0.01.
Statistical analysis was carried out using the SPSS version 10 statistical package.
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Chapter 3
A randomised controlled trial comparing heater probe
plus thrombin with heater probe plus placebo for
bleeding peptic ulcer: Re-bleeding and Mortality
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Inclusions and exclusions
Nine hundred and thirty five patients met the initial entry criteria and were
considered for entry into the trial. Of these 679 were excluded, primarily due to the
absence ofmajor stigmata of haemorrhage in the peptic ulcer. Two hundred and fifty
six patients were entered into the trial. One hundred and thirty one patients were
randomised to receive thrombin injection and the remaining 125 patients to placebo
injection. As the use of the heater probe was common to both arms of the trial, the
groups are subsequently referred to as the 'thrombin' and 'placebo' groups. Nine
patients were withdrawn because ofmajor protocol violations. In the thrombin group
three patients had received adrenaline injection in addition to the trial therapy and
one did not receive the injection of thrombin. Of these, two patients had further
bleeding requiring surgery. A gastric carcinoma was found in one case, and the
patient died two weeks later after conservative management at home. Two patients
from the placebo group had more than one ulcer requiring endoscopic therapy, one
was found to be participating in another trial, one received adrenaline in addition to
the trial therapy and one was taking anticoagulant drugs. Surgery was required for
definitive control of bleeding in both patients with multiple ulcers, and both had died
within 30-days due to cardiorespiratory complications. The other three patients had
an uncomplicated course. All these patients were removed from the final analysis
before breaking the randomisation code (Figure 3.1).
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Figure 3.1 Trial flow diagram
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The characteristics of the patients groups are shown in table 3.1. One hundred and
eight patients were treated by myself, the remaining 64 patients from Edinburgh
being entered by Dr H Dallal. Fifty nine patients were treated by Professor NAG
Mowat in the bleeding unit at Aberdeen Royal Infirmary. In Dundee, 13 patients
were treated by Dr D Johnston. Three patients were entered by Mr G Fullarton at
Gartnavel General Hospital in Glasgow. The principal research fellows (Dr Dallal
initially, followed by myself) were based in Edinburgh, and consequently, the
majority of patients entered into the trial were from this region. A number of eligible
patients from the other sites were not included due to the lack of a full time
researcher, but the disparate recruitment from the centres merely resulted in a
prolongation of the time required to randomise sufficient patients, and would not
have affected the results of the trial.
The groups were well matched for age, gender, co-morbid disease, shock,
haemoglobin, type and site of ulcer, stigmata of haemorrhage and therapy applied.
Analysis for statistical differences between the groups was not required as the
patients were randomised at entry into the trial (Prescott et al., 1999). The use of the
co-morbid disease score and the Rockall score is discussed in subsequent chapters.
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Table 3.1 Patient characteristics
Thrombin Placebo
n 127 120
Median age (range) 72 (22-94) 70 (20-92)
Sex (M:F) 84:43 84:36
Shock (%) 81 (64) 75(63)
Median co-morbid disease score (Range) 2 (0-10) 2 (0-12)
Median Rockall score (Range) 6(3-10) 5 (3-10)
Median Hb concentration (Range) g/dl 9.4 (6.2-18.1) 9.4 (4.0-14.8)
Number taking NSAIDs (%) 31 (24) 24 (20)
Median ulcer size (range) mm. 10(1-50) 10(2-50)
Gastric ulcer (%) 48 (38) 38 (32)
Duodenal ulcer (%) 72 (57) 71 (59)
Oesophageal ulcer (%) 3(2) 6(5)
Stomal ulcer (%) 4(3) 5(4)
Spurting (%) 8(6) 5(4)
Oozing (%) 41 (32) 40 (33)
Total active bleeding (%) 49 (39) 45 (38)
Non-bleeding visible vessel (%) 78(61) 75(63)
Median number ofjoules applied (range) 120 (30-420) 125 (45-300)
Median volume of injected fluid (range) ml 3.5 (2-7) 3.5 (3.5-7)
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Results
Primary haemostasis was not achieved in four patients from each group. Five of
these patients had active bleeding at the time of endoscopy. In three patients with
non-bleeding visible vessels torrential bleeding was induced by endoscopic therapy.
The outcome of therapy is shown in Table 3.2. Fifteen percent of patients re-bled in
each group. The relative risk of re-bleeding in patients receiving thrombin compared
to placebo was 1.06 (95% CI, 0.58-1.93). The difference in absolute risk of re-
bleeding between the groups was 0.8% (95% CI, - 8% - 9.6%) in favour of placebo.






Primary haemostasis (%) 123 (97) 116(97)
Re-bleed (%) 19(15) 17(15)
Emergency surgery (%) 16(13) 13(11)
30-day mortality (%) 8(6) 14(12)
Permanent haemostasis (%) 104 (82) 99 (83)
Median units transfused (range) 3 (0-32) 2(0-35)
Total units transfused 470 433
Median duration of admission (range), days 5 (2-82) 5 (1-121)
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Endoscopic re-treatment was carried out in seven patients randomised to thrombin
and in eight patients receiving placebo injections. Re-treatment was successful in
five patients from the thrombin group, although two of these subsequently required
emergency surgery for re-bleeding. In the placebo group re-treatment succeeded in
four patients, one of whom subsequently underwent surgery. In eighteen patients
repeat endoscopic treatment was not clinically appropriate. Two patients died shortly
after bleeding recurred; one died from exsanguination before treatment could be
instigated, and another very elderly frail patient was kept comfortable and not
subjected to any definitive treatment. The remaining 16 patients had extreme
bleeding and the referring clinicians felt that urgent surgery, without repeat
endoscopy, was necessary.
The numbers of patients requiring emergency surgery for bleeding were similar in
the two groups. For thrombin compared to placebo the relative risk of surgery was
1.16 (95% CI, 0.58 - 2.31). The difference in absolute risk of surgery was 1.8%
(95% CI, - 6.2% - 9.8%) in favour of placebo.
Permanent haemostasis was achieved in 104 patients (82%) in the thrombin group
and 99 patients (83%) in the placebo group.
Median blood transfusion requirements were similar in the two groups, (p = 0.69)
The duration of admission (analysed after logarithmic transformation due to the
markedly skewed distribution) was also similar in the two groups (p= 0.67).
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A subgroup analysis was performed in patients with active arterial bleeding. Table
3.3 shows outcome in relation to particular stigmata and demonstrates similar
outcome in both treatment groups. The difference in mortality in patients with active
# 2
bleeding did not achieve statistical significance (x c = 1 -4, p = 0.24).
Adverse events occurred in eight patients receiving thrombin and in four treated with
placebo (Table 3.4). Three perforations occurred; these exclusively developed in the
thrombin group and each was confirmed by laparotomy. One of these probably
occurred before endoscopy; in the other two cases perforation was an unexpected
finding during urgent surgery performed for re-bleeding. One of the perforations was
noted to be 0.5 cm from the site of heater probe therapy and the other at the site of
therapy. Five other adverse events occurred in the thrombin group; two patients
sustained myocardial infarction with a background of known ischaemic heart disease.
Three of the four patients from the placebo group who developed cardiovascular
adverse events had risk factors including previous stroke, ischaemic heart disease
and diabetes.
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Table 3.3 Outcome of treatment in relation to major stigmata









n 49 78 45 75
Primary haemostasis
(%)
46 (94) 77 (99) 42 (93) 74 (99)
Re-bleed (%) 8(17) 11(14) 5(12) 12(16)
Emergency surgery
(%)
9(18) 7(9) 5(11) 8(11)
30-day mortality
(%)
3(6) 5(6) 7(16) 7(9)
Permanent
haemostasis (%)
38 (78) 66 (85) 37 (82) 62 (83)
Median units
transfused (range)
3 (0-22) 3 (0-32) 3 (0-22) 2(0-35)
Total units
transfused




6(2-54) 5(2-82) 6(2-121) 5 (1-80)
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Table 3.4 Adverse events
Thrombin Placebo
Myocardial infarction 2 1
Pulmonary embolus 0 1
Stroke 2 2
Deep venous thrombosis 1 0
Visceral Perforation 3 0
Eight patients (6%) in the thrombin group died within 30-days compared to fourteen
patients (12%) in the placebo group (x2c = 1.6, p = 0.21). In patients treated with
thrombin the relative risk of death was 0.54 (95% CI, 0.23-1.24) compared with
those receiving placebo. The reduction in absolute risk of death was 5.4% (95% CI, -
12.5% - 1.8%) in patients receiving thrombin. Primary haemostasis had failed in
three of these twenty-two patients, and a further eleven had re-bled. Nine patients
had had an emergency operation; three for failed haemostasis and the remainder for
re-bleeding. The majority of deaths occurred from decompensation of co-morbid
disease, particularly in those patients who had undergone laparotomy. In one patient
in each group death was due to metastatic carcinoma diagnosed after the acute
bleeding episode (Table 3.5).
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Myocardial infarction 1 0
Congestive cardiac failure 2 1
Respiratory failure 2 2
Pulmonary embolism 0 1
Cerebrovascular accident 0 3
Metastatic carcinoma diagnosed
after recruitment into trial
1 1
Median Rockall score 8 8
Median co-morbid disease score 4 5
Pre-endoscopy viral serology results were available in 245 patients. Seventy six
percent of patients were antibody positive for Parvovirus B19, and 83% had
antibodies to Hepatitis A. One hundred and seventy three patients agreed to undergo
further blood sampling at six months post-injection. Of these, no patients had
seroconverted for Parvovirus B19. One patient who had previously been negative for
Hepatitis A was found to be positive. On further investigation it transpired that he
had received Hepatitis A vaccine in the intervening period. No patient seroconverted
for Hepatitis B or C.
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Chapter 4
A randomised controlled trial comparing heater probe
plus thrombin with heater probe plus placebo for
bleeding peptic ulcer: Discussion
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This placebo controlled, double blind trial showed that the efficacy of thrombin
injection plus heater probe application was similar to that of heater probe plus
placebo injection (containing albumin) in the treatment of patients admitted to
hospital because of major peptic ulcer haemorrhage. Both approaches probably
improved patient outcome since the overall re-bleeding rate and hospital mortality
were considerably lower than would have been anticipated if no endoscopic
treatment had been used (Oxner et ah, 1992). It is now unethical not to apply some
form of standard endoscopic therapy because the efficacy of this is undisputed. The
findings of this trial are similar to those reported by Chung et al. (1997), who in an
open trial showed that for the great majority of ulcer bleeding patients the
haemostatic efficacy of a combination of the heater probe plus adrenaline injection
was similar to that of adrenaline injection alone. In contrast to the thrombin study
however these authors showed in a high-risk subgroup of actively bleeding patients
that combination treatment was superior to injection treatment alone. Analysis ofmy
results in a similar way does not suggest a benefit of combination therapy even for
patients with the most severe bleeding.
In the current trial there was a trend for improved mortality in patients randomised to
thrombin and a type 2 error cannot be excluded. It is noteworthy however that the re-
bleeding rate, a commonly used end point in many trials which is strongly associated
with death following upper gastrointestinal bleeding, was identical in both treatment
groups. Furthermore other outcomes such as blood transfusion, duration of hospital
admission and requirement for emergency surgery were very similar in the two
groups. The need for operative surgery following failed endoscopic therapy in this
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study is comparable to that reported by others (Chung et al., 1997; Choudari et al.,
1992; Chung et al., 1991). These observations suggest that the small and statistically
non-significant mortality difference seen in the trial should be interpreted with
caution. Indeed a sample size of 700 patients would be required to confirm that this
is a valid difference in mortality at the 5% level of significance with an 80% power.
In this trial, particular effort was made to remove blood clot within the ulcer base in
order to accurately define and treat major stigmata. The two trials discussed in
Chapter 1 have suggested this to be a safe and effective approach, although numbers
included were small and pre-injection with adrenaline was performed (Bleau et al.,
2002; Jensen et al., 2002). In the thrombin trial clot removal without pre-injection
with adrenaline was associated with bleeding in only one of 20 patients. Spurting
bleeding was produced following dislodgement of the clot. Therapy with the heater
probe and thrombin injection was unable to produce primary haemostasis and a
partial gastrectomy was performed. The patient survived without complication.
In this study human thrombin was chosen as the injection material. This decision was
based on the theoretical considerations and clinical observations discussed in Chapter
1. The majority of clinicians inject adrenaline, which is effective but has a short
duration of action. Sclerosants and alcohol produce more extensive and prolonged
tissue damage, but these agents do not improve upon the results of adrenaline
injection and are hazardous. Thrombin given either alone or in combination with
fibrin as "fibrin glue" directly produces the desired end result of clot formation, and
clinical trial evidence is promising. It was therefore believed that these 'pro-
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coagulant' materials represented the injection treatments of choice in ulcer bleeding
patients.
Previous clinical trials of endoscopic therapy have not included a control placebo
injection. Consequently observer bias may have influenced the interpretation of some
trials. In order to determine whether combinations of therapeutic modalities of
proven efficacy, in this case the heater probe and thrombin injection, are superior to a
single modality (the heater probe) it was considered essential to include a placebo
injection and to undertake a classic double-blind randomised placebo controlled trial.
The difficulty of this approach is that we cannot know with certainty that the
'placebo' injection was devoid of haemostatic activity. The trial by Lin et al. (1993)
discussed in Chapter 1 demonstrated haemostatic effects of endoscopic injections of
50% dextrose, Normal saline and 3% Sodium Chloride. These were thought to be
due to tamponade as the mean volume of injection was 15.9ml in the saline groups.
The magnitude of the haemostatic effect of saline was questioned by the subsequent
trial by Laine et al. (2002), in which a mean volume of 30ml of saline was injected.
The results showed that even this very large volume of pharmacologically inactive
solution was inferior to thermal endoscopic therapy.
An albumin solution was chosen as the placebo fluid in order to achieve similar
protein concentrations (0.6-1.0 g/1) and viscosity in the injection fluids. There is no
reason to suspect that albumin injection would influence the clotting process. The
possibility that the placebo injection had a therapeutic effect in this trial cannot be
excluded, but pure tamponade is unlikely to have been an important factor because
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the volume of injected fluid was relatively low, and certainly much less than that
used in the trial from Lin et al. (1993). It can safely be concluded therefore that
thrombin was a no more effective adjunct to the heater probe than was placebo.
Adverse events were similar and infrequent in both treatment groups. In particular
stroke and myocardial infarction, which might have been induced by activation of
systemic coagulation following thrombin injection, were equally common in both
treatment arms and developed only in patients with pre-existing atheromatous
disease. The perforation rate was 1.2%, two perforations occurring in anterior
duodenal ulcers and the third in a posterior duodenal ulcer. This is comparable to
perforation rates reported in other series (Chung et al., 1997; Wong et al., 2002). All
three perforations occurred in the thrombin group. This is most likely to be a chance
finding as the numbers are small, and there are no previous reports of perforation
caused by injection of thrombin or fibrin glue.
No evidence virus transmission by the thrombin or placebo injections has been
demonstrated. As is the case with any blood product, there remains a theoretical risk
of transmission of unknown viruses or infectious agents. In the context of major
gastrointestinal bleeding most patients require a blood transfusion, and the additional
risk of an injection of thrombin is likely to be insignificant.
Although all patients received proton pump inhibitor (PPI) drugs following
endoscopic therapy, the use of these medications was not standardised in the trial
protocol, as the evidence for their utility in reducing re-bleeding outlined in Chapter
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1 was not available at the time of trial design. The majority ofpatients in both groups
were treated with high dose oral omeprazole. Whilst it is unlikely that differences in




Utility of the Rockall scoring system following
endoscopic therapy for bleeding peptic ulcer
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Introduction
No prospective studies have examined the utility of the Rockall scoring system in
patients undergoing endoscopic therapy for peptic ulcer bleeding, although I have
published a retrospective analysis (Church and Palmer, 2001). Since the use of
endoscopic therapy is now standard clinical practice, the ability of the Rockall score
to predict outcome following therapy is an important consideration, as many units
triage patients to the high dependency unit or the general wards based on their
Rockall scores.
The validity of a scoring system may be expressed in terms of calibration and
discrimination. In this case, calibration refers to the amount of agreement between
the rates of re-bleeding and mortality predicted by the score, and the observed rates
in the trial patients. Discrimination concerns the ability of the score to determine
which patients will re-bleed or die and which will not. Validity may also be internal
or external. Internal validity evaluates a scoring system using patients recruited from
the centre in which the system was derived, whereas external validation applies the
system to patients from other centres. It has been shown that models perform less
well when used with patients in a context outside that in which the model was
developed (Lemeshow and Le Gall, 1994), and external validation is, therefore a
more robust tool.
91
The aim of this chapter is to assess the ability of the Rockall scoring system to
predict re-bleeding and death following endoscopic therapy for bleeding peptic ulcer
in my trial population.
Methods
Rockall scores were calculated for all patients entered into the thrombin trial.
Outcome in terms of re-bleeding, surgeiy and 30-day mortality was assessed
according to score, and the association of these end-points with increasing score was
analysed using the x test for trend.
The trial patients formed a validation sample allowing the external validity of the
Rockall system to be assessed. The predicted probabilities of re-bleeding and
mortality were taken as the observed percentages of re-bleeding and mortality for
each score category in the original patient sample in Rockall's paper (presented in
table IV (B)) (Rockall et ah, 1996). Calibration of the scoring system was evaluated
using the Mantel-Haenszel test to compare the predicted and observed rates of re-
bleeding and mortality. Receiver operating characteristic (ROC) analysis was used to
assess discriminative ability. Using this method, sensitivity is plotted against 1-
specificity for each cut off value of the Rockall score. For the purposes of this
analysis, patients were classified as "low-risk" if they had a score below or equal to
each possible cut off value and "high-risk" if their score was above this (Tables 5.2
and 5.3). The area under the resulting curve (AUC) gives a measure of the
discriminative ability. An area of 50% indicates a system which is no better than
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chance alone, while a perfect discriminative model would result in an AUC of 100%.
Curves were plotted for both re-bleeding and mortality. Data analysis was performed
using the SPSS version 10 statistical package.
Results
The Rockall scores for all 247 patients in the trial followed a fairly symmetrical
distribution (Figure 5.1).
Figure 5.1 Distribution ofRockal 1 scores
U Thrombin
U Placebo
Number of patients 15
93
The mean score for the entire sample was 5.8. Because all patients had peptic ulcer
disease with active bleeding or stigmata of recent haemorrhage, the minimum
Rockall Score was three. Fifteen percent of patients re-bled within 30-days of
endoscopic therapy and nine percent died. Outcome in relation to Rockall score is
shown in Table 5.1. There was a significant relationship between the score and the
rates of re-bleeding, need for urgent surgery and the 30-day mortality (x trend = 6.22,
p = 0.01 for re-bleeding; x2trend = 9.69, p = 0.002 for surgery; x2trend = 33.3, p <
0.00001 for death) (Figure 5.2).
Figure 5.2 Outcome in relation to Rockall score
Percentage of
patients
3(20) «48> 5,54)( ' 6<37> 7(44) 8(28) 9(14> 10(2)






■ 30 day mortality
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Table 5.1 Outcome in relation to Rockall score
n Failed
haemostasis (%)
Re-bleed (%) Surgery (%) 30-day
mortality (%)
Total 247 8(3) 36(15) 29(12) 22(9)
Score 3 20 0(0) 0(0) 0(0) 0(0)
Score 4 48 2(4) 3(6) 2(4) 0(0)
Score 5 54 0(0) 8(15) 3(6) 0(0)
Score 6 37 2(5) 9(24) 11 (30) 4(11)
Score 7 44 0(0) 7(16) 4(9) 6(14)
Score 8 28 3(11) 5(18) 5(18) 5(18)
Score 9 14 0(0) 4(29) 3(21) 5 (36)
Score 10 2 1(50) 0(0) 1(50) 2(100)
Score 8+ 44 4(9) 9(21) 9(21) 12 (27)
Validation
CALIBRATION
Figure 5.3 shows the predicted probabilities of re-bleeding according to Rockall's
original patient sample compared with the observed percentages in the validation
sample. The predicted probabilities were higher than the observed re-bleeding rates
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in all risk categories, particularly for the higher score groups. There was strong
evidence that predicted and observed re-bleed rates were different (Mantel-Haenszel
test, x2 = 25.8, p < 0.0001).





3 4 5 6 7 8+
Risk score
□ Expected rebleeding based on risk scoring system □ Observed rebleeding in validation sample
Figure 5.4 shows the predicted mortality compared with the observed mortality rates.
Again the observed rates were lower than the predicted mortality, and the differences
were significant (Mantel-FIaenszel test, x = 15.1, p < 0.0001).
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3 4 5 6 7 8+
Risk score
□ Expected mortality based on risk scoring system □ Observed mortality of validation sample
DISCRIMINATION
Sensitivity and specificity for re-bleed
The Rockall score ranged from 3 to 10. The best balance between high sensitivity
and high specificity occurred when patients with Rockall scores of three to five were
considered "low-risk" and patients with higher scores were considered to be "high-
risk". The sensitivity and specificity achieved at this cut-off value were 69% and
53% respectively (Table 5.2). The ROC curve based on different cut-off values for
Rockall's score is given in Figure 5.5. The area under the curve is 63.4%. The area
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under the curve is not particularly high, and the sensitivity and specificity are not
particularly high when the best cut-off is chosen.
Sensitivity and specificity for death
The Rockall score ranged from 3 to 10. The best balance between high sensitivity
and high specificity occurred when patients with Rockall scores of three to six were
considered "low-risk" and patients with higher scores were considered to be "high-
risk". The sensitivity and specificity achieved at this cut-off were 82% and 69%
respectively (Table 5.3). The ROC curve based on different cut-off values for































































Figure 5.5 Receiver Operating Characteristic Curve for Rockall score applied to
observed re-bleed
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Figure 5.6 Receiver Operating Characteristic Curve for Rockall score applied to
observed mortality
Receiver Operating Characteristic Curve
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Discussion
The Rockall score (Rockall et al., 1996) was developed in 1996 and has been widely
adopted in clinical practice. The scoring system was developed from an analysis of
data obtained from a large audit of patients presenting with upper gastrointestinal
bleeding due to a wide range of causes and only a minority of patients received
endoscopic therapy. The current analysis was designed to determine whether the
Rockall system is applicable to the subset of high-risk ulcer bleeding patients who
receive endoscopic haemostatic therapy. It was also desirable to identify a cut off
point below which patients could be deemed to be at low-risk of poor outcome. This
is an important area because the score has been used to define prognosis, and in
particular to aid decision making in relation to patient placement in high dependency
units or the general ward.
The results of this analysis show that after endoscopic therapy higher Rockall scores
correlate significantly with re-bleeding, requirement for surgeiy and 30-day
mortality. The calibration of the system is poor, however, with significant differences
between the rates of predicted and observed re-bleeding and mortality. This is not
surprising since the two patient groups were not matched and there are thus
differences between the groups, particularly in terms of the severity and type of
bleeding, and the percentage of patients receiving endoscopic therapy. Although the
absolute percentages differ in the predicted and observed groups, the patterns of both
re-bleeding and mortality are similar, the rates rising with increasing score.
103
Of greater clinical significance is the discriminative ability of the scoring system.
This is poor when considering re-bleeding (AUC 63.4%) and meaningful
recommendations regarding patient management cannot therefore be made on the
basis of the Rockall score. In the case ofmortality the discriminative ability is much
better (AUC 84.3%), and at the cut off value of six (patients scoring six or less "low-
risk", score of seven and above "high-risk"), sensitivity and specificity for prediction
of death are adequate. When considering cut off values, however, it is important to
interpret the clinical significance of the different outcomes, and the positive and
negative predictive values of a model become more important. In this case the
clinical significance of the end-point (death) is high. It is therefore most important to
accurately predict that a patient will not die in order to triage them to a general ward
rather than to a high dependency unit following endoscopy. A more sensible cut off
point would then be a score of five because no patient scoring five or less died,
resulting in a negative predictive value of 100% (See Table 5.3). From this data it
could be recommended that patients with a Rockall score of six or greater should be
managed in a high dependency area, while those with lower scores could be
transferred to a general ward. There would be considerable resource implications in
the implementation of such a policy, and to confirm this recommendation, a
randomised trial to assess outcome in terms of post endoscopy placement would be
required.
The Rockall scoring system has been externally validated in a Dutch population by
Vreeburg et al. (1999). This study included similar patients to those used by Rockall
in the development of the score. All patients presenting with symptoms and/or signs
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or upper gastrointestinal bleeding were included, Rockall scores were calculated and
re-bleeding and mortality rates observed. These rates were then compared with
predicted re-bleeding and mortality rates from Rockall's paper. The patients in
Vreeburg's study were thus different to the patients in the thrombin trial, the latter
being restricted to high-risk patients bleeding from peptic ulcer in whom endoscopic
therapy had been applied. Despite these differences the validation results obtained in
this analysis are similar to those of Vreeburg's group. Vreeburg et al. found the
Rockall system to be poorly calibrated. In the lower score groups the predicted re-
bleeding rate was lower than the observed rate, while in the high score groups the
• 2
converse was true. These differences were significant (p<0.0001 by y goodness of
fit). Mortality rose with increasing score in both predicted and observed groups and
the differences between them were not statistically significant (p=0.2 by y goodness
of fit). The discriminative ability of the Rockall system was poor for the prediction of
re-bleeding (AUC 61%), but for mortality the AUC was 73% suggesting the main
role of the system to be the prediction ofmortality. The results ofmy analysis closely
mirror Vreeburg's results and show that although the calibration of the scoring
system may be changed following endoscopic therapy in high-risk ulcer bleeding
patients, the discriminative ability remains good for the prediction of mortality and
poor for the prediction of re-bleeding.
On first inspection the Rockall scoring system appears complicated. Despite this,
calculation of Rockall scores is straightforward, and the required information is
readily obtainable from patient records or trial databases. Co-morbid disease in the
trial patients was recorded in a different way to the classification of co-morbidity
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used by Rockall (see Chapter 2), but the detailed documentation of co-morbid
conditions in our patients allowed accurate calculation of the Rockall score.
In conclusion, re-bleeding and mortality rates correlate with Rockall scores in
patients undergoing endoscopic therapy for bleeding peptic ulcer. Patients with
scores of six or greater have a significantly poorer outcome. Calculation of a Rockall
score may be a clinically useful way to predict which patients will do badly,
facilitating decisions concerning post-endoscopy placement and monitoring.
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Chapter 6
The impact of co-morbid disease upon outcome
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Introduction
Co-morbid illness greatly influences outcome from peptic ulcer bleeding and the
majority of deaths occur in patients with significant co-morbidity. This was
particularly evident in the papers produced by Rockall et al. (Rockall et al., 1995;
Rockall et al., 1995; Rockall et al., 1996; Rockall et al., 1996). The presence of co-
morbid illness has also been reported to influence the success of endoscopic therapy
(Villanueva et al., 1993). In the study reported in this thesis, the severity of co-
morbid disease was carefully defined and scored as described in Chapter 2. In this
chapter the impact of co-morbid disease on outcome of the trial patients is analysed.
Method
The different co-morbid conditions were scored on a scale from 0-3 where 0
represents no disease, 1 represents mild disease, 2 represents moderate disease and 3
represents severe disease (see Table 2.1). The total score for each patient in the trial
was calculated and patients were separated into score groups. Outcome following
endoscopic therapy was related to total score. Because the number of patients with
scores greater than six was small, patients scoring six or above were also considered
as one group. Rates of re-bleeding, surgery and 30-day mortality in each score group
were compared using the x test for trend.
In order to assess the individual contribution of each co-morbid condition to overall
outcome, logistic regression models were produced for each of the three major end-
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points of re-bleeding, surgery and 30-day mortality. Due to the small number of
patients in certain categories the co-morbidity variables were re-coded and analysed
as "no disease" and "mild disease" combined (representing minor co-morbidity)
compared with "moderate disease" and "severe disease" combined (indicating the
presence of significant co-morbid disease). The stepwise procedure was used with
variables entering and leaving the models at the 5% significance level. Independent
predictors of re-bleeding, surgery and 30-day mortality were determined using the
j #
Wald x test and are presented as odds ratios with 95% confidence intervals. Data
analysis was performed using the SPSS version 10 statistical package.
Results
The majority of patients had low total co-morbidity scores as shown in Figure 6.1.
The number of patients with disease in each category is shown in Table 6.1.
Cardiovascular disease was the most prevalent co-morbid condition, followed by
arthritis, respiratory and neurological diseases. The other categories were represented
to a lesser extent. Moderate or severe disease was predominantly cardiorespiratory in
nature.
109
Figure 6.1 Distribution ofco-morbid disease scores
■Thrombin
□Placebo






Table 6.1 Number of patients with disease by category
Category
Number of patients with
any severity of disease
(%)
Number of patients with











OUTCOME ACCORDING TO DISEASE SCORE
The outcome in relation to the co-morbid disease score is shown in table 6.2. There
was a close relationship between increasing co-morbid disease score and rates of re-
• 9 •
bleeding, surgery and 30-day mortality (% trend = 6.817, p = 0.009 for re-bleeding,
X2trend = 9.086, p = 0.003 for surgery, x2trend= 38.44, p < 0.0001 for mortality) (Figure
6.2).
Ill
Table 6.2 Outcome in relation to co-morbid disease score (1)
n Re-bleed (%) Surgery (%) 30-day mortality
(%)
Total 247 36(15) 29(12) 22 (9)
Score 0 57 6(11) 2(4) 2(4)
Score 1 51 5(10) 4(8) 0(0)
Score 2 56 5(9) 5(9) 3(5)
Score 3 42 11 (26) 11 (26) 5(12)
Score 4 17 4(24) 3(18) 1(6)
Score 5 11 1(9) 0(0) 4(36)
Score 6 4 2(50) 2(50) 2(50)
Score 7 4 0(0) 1(25) 2(50)
Score 8 1 0(0) 0(0) 1 (100)
Score 9 2 0(0) 0(0) 1(50)
Score 10 1 1 (100) 0(0) 0(0)
Score 11 0 0(0) 0(0) 0(0)
Score 12 1 1 (100) 1 (100) 1 (100)








When patients with scores of six or above were considered as one group the results
were similar (x2 trend = 5.376, p = 0.02 for re-bleeding, x2trend = 8.995, p = 0.003 for
surgery, x,2 trend= 33.29, p < 0.0001 formortality) (Table 6.3, Figure 6.3).
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Table 6.3 Outcome in relation to co-morbid disease score (2)
n Re-bleed (%) Surgery (%) 30-day mortality (%)
Total 247 36(15) 29(12) 22 (9)
Score 0 57 6(11) 2(4) 2(4)
Score 1 51 5(10) 4(8) 0(0)
Score 2 56 5(9) 5(9) 3(5)
Score 3 42 11 (26) 11 (26) 5(12)
Score 4 17 4(24) 3(18) 1(6)
Score 5 11 1(9) 0(0) 4(36)
Score 6 or greater 13 4(31) 4(31) 7(54)



















EFFECT OF DIFFERENT CO-MORBID CONDITIONS
Re-bleeding
When 'no disease' was combined with 'mild disease' and compared with 'moderate
disease' and 'severe disease' combined then neurological disease was the only co¬
morbidity which predicted re-bleed when each co-morbidity was considered
separately (%2 test with continuity correction 7.1, p = 0.008). The odds ratio of re-bleed
was four for moderate/severe cases compared to those who had only mild disease. In
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stepwise logistic regression, neurology and cancer were significant independent
predictors of re-bleeding (Table 6.4).
Table 6.4 Significant independent predictors of re-bleed
Co-morbidity
Moderate/severe disease compared to none/mild disease
Wald x2 P OR (95% CI)
Neurological 8.75 0.003 5.11 (1.73, 15.1)
Cancer 4.64 0.031 3.65 (1.12, 11.9)
Surgery
When 'no disease' was combined with 'mild disease' and compared with 'moderate
disease' and 'severe disease' combined, then neurological disease was associated
with surgery (% test with continuity correction 5.1, p = 0.023) with an odds ratio of
four for moderate/severe cases compared to those who had no disease or mild disease
(OR 4.33, 95% CI 1.37, 13.7). In stepwise logistic regression, neurological and
respiratory diseases were significant independent predictors of surgery (Table 6.5).
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Table 6.5 Significant independent predictors of surgery
Co-morbidity
Moderate/severe disease compared to none/mild disease
Wald x2 P OR (95% CI)
Neurological 6.70 0.010 4.71 (1.46, 15.2)
Respiratory 4.67 0.031 3.15 (1.11, 8.91)
30-day mortality
When 'no disease' was combined with 'mild disease' and compared with 'moderate
disease' and 'severe disease' combined then those with moderate or severe
respiratory disease (% test with continuity correction 6.1, p = 0.014, OR 3.58, 95% CI
1.39, 9.23), heart disease (y2 test with continuity correction 23.0, p < 0.001, OR 9.69,
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95% CI 3.57, 26.3), and neurological disease (% test with continuity correction 15.2,
p < 0.001 OR 9.00, 95% CI 2.85, 28.5) had increased odds of 30-day mortality
compared to those without the diseases/conditions. In stepwise logistic regression,
respiratory, neurological and renal diseases were significant independent predictors of
30-day mortality (Table 6.6).
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Table 6.6 Significant independent predictors of 30-day mortality
Co-morbidity
Moderate/severe disease compared to none/mild disease
Wald x2 P OR (95% CI)
Respiratory 21.3 <0.001 14.5 (4.65, 44.9)
Neurological 18.1 <0.001 16.9 (4.60, 62.0)
Renal 5.18 0.023 11.8(1.41,99.0)
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Discussion
The co-morbid disease score used in this study includes disease of all major organ
systems, recent surgery and trauma. Although an arbitrary score is allocated to the
severity of disease within each system, the complete score is a comprehensive index
of a patient's state of health rather than a simple grading of co-morbidity into
"minor" or "major" categories.
This analysis suggests that poor outcome following endoscopic therapy for major
upper gastrointestinal bleeding is correlated with the extent of a patient's co-morbid
disease. The previously published risk scoring systems discussed in Chapter 1
(Rockall et al., 1996; Saeed et al., 1993; Pimpl et ah, 1987; Garripoli et al., 2000;
Guglielmi et al., 2002) universally include co-morbid disease as a major component,
supporting its importance as a predictor of poor outcome. Logistic regression
analysis demonstrates that significant neurological conditions and malignancy are
independent predictors of re-bleeding. Similarly, neurological and respiratory co¬
morbidity is associated with requirement for surgery and the presence of
neurological, respiratory and renal disease is predictive of 30-day mortality.
In the published papers (Rockall et al., 1996; Saeed et al., 1993; Pimpl et al., 1987;
Garripoli et al., 2000; Guglielmi et al., 2002), cardiac failure, ischaemic heart
disease, renal failure, liver failure and malignancy are the most significant co-morbid
conditions affecting outcome. In this study, significant liver disease and widespread
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malignancy were excluded, but patients with mild liver disease and localised or
treated cancer were included.
In this patient group, neurological disease appears to be the most important co-
morbid condition, affecting re-bleeding, surgery and mortality. The majority of
patients in this trial with significant neurological co-morbidity had suffered a recent
or acute stroke. It is unlikely that stroke per se would predispose to failure of
endoscopic therapy, although nutritional deficiencies resulting in poor wound healing
could be implicated. A more plausible explanation is that stroke is a marker ofmore
generalised vascular disease. There is a strong association between cerebrovascular
disease and vascular disease elsewhere, one study showing that 35% of patients with
symptomatic cerebrovascular or carotid artery disease also had severe coronary
artery disease which was often asymptomatic (Graor et al., 1998). Generalised
vascular changes in our trial patients could have affected the responsiveness of
involved blood vessels to endoscopic therapy. If should be noted, however, that
pathological specimens of resected ulcers do not demonstrate significant
atherosclerotic changes in the bleeding vessels (Swain et al., 1986) (see Chapter 1).
A number of other important factors could have resulted in an increased mortality in
these patients. Stroke results in cardiac complications which are not due to
underlying coronary artery disease. These include repolarization and ECG
abnormalities (Goldstein, 1979), cardiac arrhythmias (Rem et al., 1995) and
neurogenic cardiac damage (Oppenheimer and Norris, 1995). In addition, respiratory
complications are common following stroke and include aspiration pneumonia,
abnormal respiratory patterns and more rarely neurogenic pulmonary oedema.
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Respiratory conditions confer a high-risk of poor outcome probably due to reduced
tolerance of sedation and general anaesthesia with resultant tissue and end-organ
hypoxia.
The presence of localised or treated cancer was predictive of re-bleeding but not
mortality. This is likely to be due to the fact that patients with widespread
malignancy were not included in the trial. Malignancy may be associated with re-
bleeding due to nutritional deficiencies resulting in impaired tissue healing. In
addition, many tumours have been shown to be associated with impaired coagulation
due to acquired inhibitors of factor VIII (Sallah and Wan, 2001) factor V (Knobl and
Lechner, 1998), although levels of these factors were not measured in my patients.
Renal failure is associated with poor tissue healing, generalised vascular disease,
cardiac failure, and multiple other reasons for poor outcome. It is, therefore, not
surprising that this condition is an independent predictor of mortality.
The fact that cardiovascular co-morbidity was not independently associated with re-
bleeding or requirement for surgery might suggest that generalised vascular disease
does not play a major role in failure of endoscopic therapy. The lack of association of
cardiovascular disease with mortality was unexpected. The sample contained enough
patients with cardiovascular disease to make valid comment, but of the 122 patients
with cardiovascular disease, 83 had disease in the "mild" category. It is possible that
the result would have been different had more patients with moderate or severe
cardiovascular morbidity been included.
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Further studies would be required to define the individual importance of the different
co-morbid conditions contributing to the overall disease score used in this trial. This
could allow for "weighting," with more important conditions contributing greater
numbers to the overall score than those with lesser influence. In its present form the
score appears to be clinically useful, with rising scores correlating with increased
rates of re-bleeding, surgery and mortality. It would be desirable to prospectively
validate the score in an independent group of patients. In studies of endoscopic
therapy for GI bleeding, differences in end points are small. It is therefore important
to restrict entry into trials of endoscopic therapy to only those patients at highest risk
for failure of therapy. It is also important to ensure that groups within trials are as
closely matched as possible, and that results of trials in different populations can be
compared. With further refinement, this co-morbid disease score could be used in
conjunction with clinical parameters to facilitate both these goals.
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Chapter 7
Use of the heater probe for bleeding peptic ulcer -
effect of heater probe diameter
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Introduction
The heater probe (Olympus HPU, Olympus Corporation, Melville, NY) is a contact
thermal device which is inserted down the biopsy channel of an endoscope. The
probe is 3m long and is produced in 2.4mm and 3.2mm diameters. The probe tip
consists of a rigid section 15mm long with 3 irrigation nozzles at the proximal end,
allowing irrigation in an umbrella fashion at a series of preset levels controlled by a
foot switch. The distal end of the tip consists of a brass cylinder with a rounded end.
This contains an avalanche diode which is heated when the foot switch is depressed.
The diode enables rapid heating to a defined temperature and then switches off the
current when a preset amount of energy has been delivered. Initial versions of the
probe heated the tip to 150 °C while the current version heats to 250 °C. The
temperature at the tip is maintained until 5-30 joules have been delivered. The probe
delivers 30 J in 8-10 seconds in air, this falling to 3-5 seconds when immersed in
water. In order to minimise adherence to treated tissue the tip is Teflon coated. A
standard therapeutic technique has been adopted for treatment of peptic ulcers with
active bleeding or non-bleeding visible vessels (Johnston et al., 1985). The probe is
used to firmly tamponade the bleeding point and is then activated at the 20-30 J
setting. Two to three applications are applied before moving the probe and
reapplying therapy. Treatment is continued until bleeding has ceased and the
bleeding point is blackened and cavitated.
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EXPERIMENTAL USE OF THE HEATER PROBE
Use of the heater probe was first reported by Protell et al. (1978). The probe was
used to treat experimental ulcer bleeding and the 3.2mm probe stopped bleeding in
18 of 19 ulcers. Further experimental work involved an experimental model of acute
peptic ulceration using canine mesenteric arteries. In 1984 Johnston et al. reported a
trial which compared the effects of laser, monopolar and bipolar electrocoagulation
(BICAP), electrofulguration and heater probe on experimental arterial bleeding. The
most effective approach was that of coaptive coagulation, in which the bleeding
vessel is first compressed before heat is applied. The heater probe and the bipolar
probe were found to be equivalent and superior to the other methods, and had a lesser
degree of undesirable tissue erosion. This was followed up with a trial comparing the
heater probe with the BICAP (Johnston et al., 1985). The two modalities were found
to be similar, but bond strength with the heater probe was greater than that for the
BICAP (1459 vs 765 mmHg), and the heater probe was associated with a lesser
degree of tissue adherence. These results are supported by those of Swain et al.
(1984) in a similar study. Two experimental studies assessed the efficacy of probes of
different sizes. Morris et al. (1985) compared the effects of the 2.3mm and 3.2mm
BICAP probes on canine arteries. The 3.2mm probe was more effective for vessels
which were 1.2mm in diameter or larger. A study by Jensen et al. (1982) concluded
that the 2.4mm and 3.2mm heater probes were similar in efficacy.
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CLINICAL TRIALS
The important clinical trials involving the heater probe are discussed in Chapter 1.
The trial by Matthewson et al. (1990) is the only clinical trial to include an
assessment of the outcome according to size of heater probe used. One hundred and
forty three patients were randomised to one of Nd-YAG laser, heater probe or
conservative therapy. During this trial the randomisation proportions were altered to
three heater probe: one laser: one control, in order to increase the power of the
comparisons between heater probe and control, and heater probe and laser. While the
laser treated patients had a significantly lower re-bleeding rate than the control group
(20% versus 43%), a significant advantage was not demonstrated for the heater probe
group (Table 1.12). Of the 57 patients randomised to the heater probe, 42 were
treated with the 3.2mm probe. In the remaining 15 patients the 2.4mm probe was
used due to lack of availability of an endoscope with a large biopsy channel. Re-
bleed rates in the large and small probe groups were 24% and 40% respectively.
These were not significantly different from the control group (43%) but
demonstrated a trend in favour of the large diameter probe.
RATIONALE
Experimental studies using canine models have suggested that thermal endoscopic
haemostatic methods are only effective in arteries up to 2mm in diameter (Swain et
al., 1984; Michaeletz and Judge, 1989; Johnston et al., 1987). Studies on post¬
operative resection specimens reveal that the majority of ulcer bleeding arises from
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vessels with a diameter of less than 2mm (Swain et al., 1986), but when post-mortem
ulcers are examined, vessels up to a diameter of 3.45mm have been reported (Lai and
Swain, 1993). It is logical to propose that the large heater probe should be more
effective than the small probe, and it has been stated that the 3.2mm probe is required
for optimum effect (Chung et ah, 1997). There is experimental support for this view
(Morris et ah, 1985), but a lack of clinical trial evidence. This analysis aims to
further define the outcome of endoscopic therapy according to size of heater probe
used.
Method
The trial reported in this thesis shows that the combination of heater probe with
human thrombin injection is no better than the combination of heater probe with
placebo injection. In this trial the majority of patients were treated with the 2.4mm
probe due either to lack of availability of a large probe, or to lack of availability of a
large endoscope. In order to assess the possible effect of probe diameter on outcome
of treatment, the results were analysed in relation to size of probe used. The patients
were divided into two groups. Group A consisted of those patients treated with the
2.4mm probe, while the remainder were designated as group B.
Statistical analysis
Baseline characteristics of the study groups were compared using the Mann-Whitney
• • 2 • •
test for continuous variables, and the % test with Yates' correction for categorical
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variables. Differences in proportions for the study outcomes were analysed using the
X2 test with Yates' correction, and were considered significant at a p value of less
than 0.05. Data analysis was performed using the SPSS version 10 statistical package.
Results
Two hundred and sixteen patients were treated using the 2.4mm probe; the 3.2mm
probe was used in the remaining 31 patients. No technical problems were
encountered when using the large channel endoscope, and all lesions were accessible
to treatment. Table 7.1 shows the characteristics of the two groups. Group A
contained a small number of patients with oesophageal ulcers and fewer patients in
this group received thrombin as the injection material. A greater number of patients
in group A had suffered a bleed while in hospital. None of these differences were
significant. The groups were well matched for the other factors associated with
severity of a bleeding episode, specifically the presence of shock, co-morbid disease
severity, ulcer size, presence of duodenal ulcer and active bleeding. The only
statistically significant difference between the groups was in the volume of injection
used.
Table 7.2 shows the outcome according to probe size. Haemostasis failed in eight
patients in group A. Five of these presented with actively bleeding ulcers. In the
remaining three patients endoscopic therapy induced torrential bleeding which could
not be controlled. Emergency surgery was carried out in six of the eight patients and
three had died within 30-days. Primary haemostasis was successful in all patients in
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the group B. There was a trend towards a reduction in re-bleed rate in group A but
this did not achieve statistical significance (x c = 1-164, p = 0.28). Similarly, there
was a non-significant trend towards reduction in surgery in the small probe group.
Mortality rates were equivalent in the two groups.
Adverse event rates were similar in the groups (5% in group A versus 7% in group
B). Three perforations occurred, all in group A. These patients all were bleeding
from duodenal ulcers and had received injection with thrombin and a median of 120
J of therapy with the 2.4mm probe. One perforation was thought to have been present
prior to endoscopic therapy.
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Table 7.1 Characteristics of patients treated with small and large heater probe
Small probe Large probe P
n 216 31 -
Median age (range) 72 (20-94) 75 (34-92) 0.92
Shock(%) 137 (63) 19(61) 0.96
Median (range) haemoglobin (g/dl) 9.3 (6.2-18.1) 9.65 (4.0-14.4) 0.66
Median co-morbid disease score (Range) 2 (0-12) 2 (0-7) 0.90
Median Rockall score (Range) 5.5 (3-10) 6 (3-8) 0.97
Median (range) ulcer size (mm) 10(1-50) 10(3-50) 0.33
GU (%) 72 (33) 14 (47) 0.49
DU (%) 127 (59) 16(52) 0.81
Oesophageal (%) 9(4) 0(0) 0.54
Stomal (%) 8(4) 1(3) 0.70
Spurting (%) 11(5) 1(3) 1.00
Oozing (%) 70 (32) 11(35) 0.96
Total active bleeding (%) 81 (38) 12(39) 0.92
NBVV(%) 135 (63) 19(61) 0.92
Median (range) HP joules 120 (30-420) 160 (80-280) 0.33
Median (range) injection volume 3.5 (2-7) 3.5 (3.5-7) 0.02
Out of hours scope (%) 66 (31) 10(32) 0.96
In hospital bleed (%) 35(16) 2(7) 0.32
Thrombin (%) 108 (50) 19(61) 0.63
Adverse events (%) 10(5) 2(7) 0.97
Perforation (%) 3(1) 0(0) 1.00
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Table 7.2 Small vs large heater probe
Small probe Large probe X2c P Relative risk (95%
confidence interval)
n 216 31 - " -
Failed haemostasis (%) 8(4) 0(0) 0.299 0.59 0.00 (0.00, 4.15)
Re-bleed (%) 29(13) 7(23) 1.164 0.28 1.68 (0.81,3.51)
Surgery (%) 23 (11) 6(19) 1.232 0.27 1.82 (0.80, 4.11)
30-day mortality (%) 20 (9) 2(7) 0.031 0.86 0.70 (0.17, 2.84)
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Discussion
Most trials involving the heater probe have used the large probe. In order to use the
large probe a specialised endoscope with a 3.7mm working channel is required. This
may have a number of disadvantages. Firstly a large channel endoscope may not be
available in all endoscopy units. Secondly intubation with the large channel
endoscope is more difficult as compared to the standard instruments, especially in
older frailer patients. Most importantly, the larger endoscope is stiffer and less
manoeuvrable which may render some lesions, particularly those in the duodenal cap
untreatable.
In this trial the large channel therapeutic endoscope was used in preference to a
standard model when available. It was possible to intubate all patients successfully,
and visualisation of the bleeding lesion was generally better due to increased
capacity for clearing fresh and altered blood, and the ability to irrigate and aspirate
simultaneously. All lesions were accessible to therapy despite the reduced
manoeuvrability of the endoscope.
The results of this analysis suggest that in combination with an injection agent the
small heater probe is as effective as the large probe. It must be acknowledged,
however that the original trial was not primarily designed to determine the effect of
heater probe diameter and there is a considerable disparity in the number of patients
in the two arms of this analysis. This study therefore has a low power to detect
differences between the treatments, should any exist, and the confidence intervals for
132
the relative risks presented in table 7.2 are wide. In addition, because patients were
not randomised to receive therapy with either the small or the large probe, there may
be important differences between the groups.
There were more oesophageal ulcers in the small probe group, but all these ulcers
had active bleeding or visible vessels, and the patients had fulfilled the strict entry
criteria limiting entry to the trial to those with high-risk bleeding. Had these patients
not been present the results would be unchanged.
Fewer patients treated with the small probe had received thrombin injection. The
overall results of the trial however, show that in combination with the heater probe,
thrombin and placebo injections have similar efficacy. Thrombin was certainly not
shown to have a detrimental effect on outcome, and theoretically therefore group A
might have been expected to fare worse as they had not received an active
therapeutic agent. A further discrepancy between the groups is the increased
proportion of group A patients developing bleeding while hospitalised for another
condition. This has been shown to be an independent predictor of poor outcome and
should bias the results in favour of patients treated with the large probe.
Patients in group A received a slightly smaller volume of injection than those in
group B. The difference in the mean volumes of injection was 0.3ml. While this
difference was statistically significant it is unlikely that clinically important effects
would have resulted. It has been shown that larger injection volumes tend to reduce
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re-bleed rates (Lin et al., 2002) and, like the other matching differences between the
groups, this would be expected to favour group B.
The trial investigators documented ulcer size but did not attempt to quantify the size
of visible vessels, as accurate endoscopic assessment of size is impossible when
lesions are only millimetres in diameter. It is possible that there were differences in
the mean size of the vessels in the two groups, this being a further potential source of
bias.
In conclusion, this analysis should be interpreted with caution due to confounding
factors and low power. A definitive statement regarding the effect of heater probe
size would require the performance of a randomised trial in which patients with
bleeding peptic ulcer were randomised to combination treatment with injection
therapy and either the large or the small heater probe.
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Chapter 8
Prediction of therapeutic failure
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Introduction
Endoscopic therapy for bleeding peptic ulcer is successful in the majority of patients,
but those patients in whom primary haemostasis is not achieved, or bleeding recurs
are at an increased risk of death (Balanzo et al., 1988; Panes et ah, 1987; Chung et
ah, 1998; Oxner et ah, 1992; Moreto et ah, 1992; Swain et ah, 1986; Laine 1987)).
Failure of primary haemostasis is readily apparent and in most cases the patient is
referred for surgery. Secondary failure of endoscopic therapy (re-bleeding) is
managed by repeat endoscopic therapy or surgery. There may be a significant time
between the onset of further bleeding and the development of clinical signs of shock,
haematemesis, melaena or a fall in haemoglobin. This plus the time involved in
organising repeat endoscopy may result in delays in the diagnosis of re-bleeding and
application of definitive therapy. Analysis of the data presented in this thesis, in
common with those from multiple other randomised clinical trials, suggests that the
haemostatic efficacy of endoscopic therapy is largely unrelated to the current
methods employed, and that failure of endoscopic therapy occurs in 15-20% of
patients. Accurate prediction of therapeutic failure in these high-risk patients could
influence intensive monitoring and treatment strategies with the potential to improve
overall outcome.
This chapter examines various clinical and endoscopic characteristics of the patients
entered into the thrombin trial in order to define those associated with re-bleeding.
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Method
All patients in whom primary haemostasis had been achieved were included. Re-
bleeding was defined as described in Chapter 2.
Outcome following endoscopic therapy was analysed according to a number of clinical
and endoscopic variables, with the trial patients divided into groups according to each
of the following:
Age (< 60 vs > 60 years)
Presence of shock (yes vs no)
Presence of co-morbid disease (all category scores 0 or 1 vs > score 2 or 3)
Haemoglobin (< lOg/dl vs > lOg/dl)
Rockall score (< 6 vs > 6)
Ulcer size (< 20mm vs > 20mm)
Bleed from a posterior duodenal ulcer (yes vs no)
Bleed from a high lesser curve gastric ulcer (yes vs no)
Presence of active bleeding (yes vs no)
For definitions of shock and classification of co-morbid disease see Chapter 2. Rockall
score was calculated as in Table 1.1. The ulcer size was estimated by comparing the
ulcer base to the length of the brass cylinder at the distal end of the heater probe tip
(10mm). High lesser curve ulcers were those on the lesser curve of the stomach close to
the cardia. Ulcers located in the duodenal bulb and positioned in the right side of the
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endoscopic view between 12 o'clock and 6 o'clock relative to the gastric incisura were
termed posterior duodenal ulcers.
Univariate analysis was used to assess the strength of association of each variable
with the outcome of endoscopic therapy. This was undertaken by comparing the
percentages of re-bleeds in the groups for each variable (e.g. haemoglobin <10g/dl and
•2
haemoglobin >10g/dl). Differences in percentages were analysed using the % test.
Variables with p values less than 0.2 were then entered into a stepwise logistic
regression model, and were considered to be significant independent predictors of
outcome when p < 0.05. Data analysis was performed using the SPSS version 10
statistical package.
Results
Of the 247 patients entered into the trial, primary haemostasis was achieved in 239
(97%). Re-bleeding occurred in 36 patients. Three of these exsanguinated before
definitive therapy could be carried out and one was unfit for further intervention.
Twenty three patients underwent urgent surgery. Fifteen patients were managed by
repeat endoscopic therapy and this was successful in six. In the remainder, re-bleeding
was definitively controlled by surgical operation (Figure 9.1).
Univariate analysis of variables showed that re-bleeding was associated with moderate
or severe co-morbid disease, Rockall score at least 6, ulcer size greater than 20mm and










Failedbut notfitor surgery 1(dieddue
tobleeding)
Spontaneous resolutionof bleeding 1
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Table 9.1 Univariate analysis: factors related to re-bleeding
Predictor Category n Re-bleed, n (%) X2 test, p OR (95% CI)
Age
< 60 years 67 9(13)
0.36
1.00





Yes 156 32 (21) 1.70 (0.83,3.49)
Presence of co-
morbid disease
All no/mild 163 19(12)
0.001
1.00





>6 125 25 (20) 2.52 (1.18,5.39)
Haemoglobin
> 1Og/dl 87 11 (12.6)
0.15
1.00
<1Og/dl 158 33 (20.9) 1.82 (0.87,3.82)
Ulcer size
<10mm 81 11 (13.6)
0.30
1.00























Yes 93 18(19.4) 1.18 (0.61,2.30)
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Further analysis using multiple logistic regression revealed that the presence of
moderate or severe co-morbid disease in any system, ulcer size greater than 20mm and
the presence of a posterior duodenal ulcer were significant independent predictors of re-
bleeding (Table 9.2).





Category n* Re-bleed, n
(%)*





>20mm 36 15 (41.7) 3.57 (1.59, 8.03)
Presence of co-
morbid disease
All no/mild 163 19(11.7)
0.006
1.00






Yes 63 20 (31.7) 2.52 (1.22,5.19)
* Percentages are based on those in the univariate analysis
141
Discussion
Factors associated with failure of endoscopic therapy for bleeding peptic ulcer have
been the subject of a number of published papers (Villanueva et al., 1993; Choudari et
ah, 1994; Hsu et ah, 1994; Brullet et ah, 1996 (Gut); Brullet et ah, 1996 (Gastrointest
Endosc); Chung IK et ah, 2001; Wong et ah, 2002). There are methodological
differences between these studies and the current analysis, but the patient inclusion
criteria are similar and my results are similar to those of others.
In Chapter 5 the presence of co-morbid disease was shown to be associated with re-
bleeding, surgery and death. Neurological disease and malignancy were significant
independent predictors of re-bleeding. Impaired wound healing and coagulation
mechanisms may explain the association of co-morbid disease with re-bleeding. It is,
therefore, not surprising that co-morbidity is a significant independent predictor of re-
bleeding in this analysis. These results are similar to those of Villanueva et al (1993).
This group noted that patients with co-morbid conditions were more likely to have
larger ulcers, and ulcers in the posterior duodenum. This is also the case in my patients,
but despite this, the effect of co-morbidity persisted after multivariate analysis. Other
studies have not demonstrated co-morbid illness to be an independent predictor of re-
bleeding, the effect on mortality being more significant (Brullet et al., 1996
(Gastrointest Endosc)).
Ulcer size is the most frequently reported predictor of re-bleeding. Ulcers greater than
20mm in diameter were significant independent predictors of failure of therapy in four
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of the seven published papers. (Brullet et al., 1996; Brullet et ah, 1996; Chung et ah,
2001; Wong et al., 2002) A fifth paper found ulcer diameter greater than 10mm to
predict failure. (Villanueva et al., 1993) Measurement of ulcer size may be subject to
error, but in practice it is relatively straightforward to estimate the diameter of an ulcer
base compared to the known length of the heater probe tip. This technique may not
yield reproducible measurements correct to one or two millimetres, but will reliably
differentiate large ulcers from small ones, and is the type of approach most readily
applicable to routine clinical practice. Large ulcers are usually deeper and contain larger
vessels than small ulcers. This may adversely affect outcome in three ways. Firstly,
deep ulcers may be difficult to approach in order to adequately apply endoscopic
therapy. Secondly, larger ulcers tend to be more chronic and fibrous, rendering
endoscopic therapy more difficult to apply. Thirdly, endoscopic therapy has been
shown to be less effective when applied to larger vessels (Hepworth et al., 1998).
Ulcer position has been shown to influence re-bleeding in three papers (Choudari et al.,
1994; Villanueva et al., 1993; Chung et al., 2001). Choudari et al. found that the
proportion of patients bleeding from a posterior duodenal ulcer was higher in those
patients who re-bled after endoscopic therapy. This observation was not subjected to
multivariate analysis. Chung et al. found that the presence of a gastric ulcer was
predictive of re-bleeding, but again only in the univariate analysis. Only the paper by
Villanueva et al. demonstrated the presence of a posterior duodenal ulcer to be
predictive of re-bleeding after multivariate analysis. The association of posterior
duodenal ulcer with poor outcome is logical because large ulcers in this area erode into
branches of the posterior duodenal artery and produce severe bleeding. In addition, the
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posterior part of the duodenal bulb is often difficult to approach, requiring tangential
application of therapy and limiting the efficacy of certain therapeutic methods.
The accuracy of endoscopic localisation of a duodenal ulcer to a particular part of the
bulb has been questioned by Straker et al. (1992). This study concluded that a single
experienced endoscopist correctly identified the posterior duodenum in as few as 30%
of cases. This observation was based on a series of only 20 patients in whom
laparotomy was not performed to confirm the ulcer site, and the result has not been
verified. I found the previously described system for localisation of the ulcer within the
duodenal bulb straightforward, and in those patients undergoing surgery after failed
endoscopic therapy the position of the ulcer documented by the endoscopist was correct
in the majority, although the operation note did not state the exact position of the ulcer
in all cases.
Whilst the positive findings of this analysis are not surprising, other factors which might
have been expected to adversely affect the performance of endoscopic therapy were not
independently associated with failure.
The presence of shock on admission has been reported as an independent predictor in
three papers (Hsu et al., 1994; Brullet et al., 1996; Wong et al., 2002). In all these
publications shock was deemed to be present only when hypotension was evident. In
my patients the definition of shock was broader, including tachycardia as a marker of
cardiovascular compromise. Thus the group with "shock" may have included patients
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with less severe bleeding, resulting in a lack of effect for this variable in my patient
group.
Active bleeding has also been shown to predict therapeutic failure in three previous
reports (Brullet et ah, 1996; Chung et al., 2001; Wong et ah, 2002). Differences in the
definition of active bleeding, interobserver variation in reporting of endoscopic stigmata
and differences in the proportions of patients with spurting and oozing haemorrhage
could all account for the differences between these analyses and my own.
Whilst older patients have a greater degree of co-morbid disease, age itself was not an
independent factor predictive of therapeutic failure. Resection specimens of ulcers do
not contain significant atheroma (Swain et ah, 1986) and in the elderly the immediate
response to haemostatic therapy is similar to that of younger patients. Increasing age
was more closely linked to mortality.
This analysis demonstrated that endoscopic therapy is less effective in patients with co-
morbid conditions, and in those who have bled from large posterior duodenal ulcers. In
my patient group there were six patients with all these risk factors. Primary haemostasis
was achieved in all patients but all re-bled. Five of these patients required surgery and
two died. More intensive strategies such as elective repeat endoscopic therapy or even





A literature review (Chapter 1) reveals that several endoscopic therapies have been
used to manage peptic ulcers. Injection agents are the most straightforward to use;
they are portable and cheap. Thrombin injection is theoretically attractive and its use
in combination with adrenaline is supported by a previous clinical trial. The trial
reported in this thesis (Chapters 2-4), however, does not support the use of thrombin
as an adjunct to the heater probe, as the results obtained are no better than those
achieved with adjunctive placebo injection. Whilst it is unlikely that the placebo
injection had significant haemostatic effects, a type 2 error could be present. No
pharmacologically active compounds were present in the placebo solution, and the
injected volumes were small. Although thrombin injection was not proven to be
effective, neither did it have significant adverse effects. This includes a lack of
demonstrable virus transmission, although the theoretical possibility exists of
transmission of as yet unknown viruses or other infectious agents. The findings do
not necessarily imply that thrombin injection is ineffective, but show that the
combination of thrombin injection plus heater probe is not superior to heater probe
plus placebo injection.
The heater probe is an effective and safe instrument. It can be particularly useful
when therapy is applied tangentially. The high pressure washing jet and the ability to
tamponade a bleeding vessel facilitate visualisation and initial control of the bleeding
point. The analysis in this thesis (Chapter 7) suggests that the small diameter probe
may be as effective as the larger probe when combined with endoscopic injection.
Further studies are necessary to definitively address this question, since as stated in
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Chapter 7 my study was a retrospective analysis with a low power and potential for a
type 2 error.
My findings in relation to the Rockall scoring system (Chapter 5) were entirely
expected. Endoscopic therapy improves outcome and, therefore the re-bleed and
mortality rates predicted by the Rockall system are higher than those observed after
thermal and injection therapy for bleeding ulcers. Despite this, the pattern of
increasing re-bleed and mortality rates with increasing score persists. The system can
be used to accurately predict mortality but not re-bleeding in patients who have
received endoscopic therapy. ROC curve analysis suggests that patients scoring six
or greater should be monitored closely in a high dependency area, whereas those
with lower scores could be managed on a general ward. This has practical value and
could be incorporated into local or national guidelines.
It is not surprising that co-morbid conditions have a major impact on both the
success of endoscopic therapy and survival following an episode of major bleeding.
Neurological conditions (predominantly acute stroke), respiratory disease,
malignancy and renal failure were independently associated with poor outcome
(Chapter 6). There may not have been sufficient numbers of patients in the study
population with cardiovascular disease severe enough to affect outcome. The co¬
morbidity score discussed in this thesis requires refinement and validation. A
detailed score categorising the severity of co-morbid disease would be a useful tool
to enable investigators to properly compare study populations in different areas of
the world.
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Accurate prediction of failure of endoscopic therapy could allow those patients at
highest risk to be offered semi-elective surgery after initial control of bleeding.
Multiple studies have addressed the problem of prediction of failure of endoscopic
therapy, but unfortunately consistent factors conferring a high-risk have not emerged.
Re-bleeding is a relatively infrequent event even in high-risk patients, and the
numbers of patients in the published trials is consequently small. My own analysis
(Chapter 8) contains 36 patients, and the other seven published trials contain only a
total of 324 patients. My findings - that re-bleeding occurs in patients with
significant co-morbid disease and large ulcers located near large arteries - were
consistent with those of most other studies. Since the majority of patients do not re-
bleed after successful endoscopic therapy, and accurate predictive factors of poor
outcome are not defined, the best policy remains one of close observation rather than
semi-elective surgery in selected patients.
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Future Work
1. The most recent meta-analysis to study endoscopic therapy in general was
published by Cook et al. in 1992. An up to date meta-analysis including the
many recent trials is required.
2. None of the existing agents used for endoscopic injection have been shown to
be better than dilute adrenaline. It is possible that a significant proportion of
the effect of an endoscopic injection relates to tamponade of the bleeding
vessel, but the current agents in use are rapidly cleared from the injection site.
New agents which persist for a longer time may be more effective. One such
agent is sodium hyaluronate. This has recently been used to facilitate en bloc
resection of superficial gastric and colonic tumours (Yamamoto et al., 2003),
and to endoscopically treat vesico-ureteric reflux in children (Kirsch et al.,
2003). A pilot study using animal models of peptic ulcer bleeding is required
in the first instance.
3. It is unlikely that the results of thermal methods of endoscopic therapy will
improve sufficiently to make a major impact on outcome. I feel that future
work on non-injection methods should be directed towards mechanical
methods such as the haemoclip. Trial data are conflicting regarding the use of
the haemoclip in its current form, but refinement of the mechanism of
orientation, development of the newer three prong design and improvement in
the force exerted by the closed clip may improve results.
150
4. A problem common to most trials of endoscopic therapy is that of small size.
Multi-centre collaborative trials are required in order to include large
numbers of patients and convincingly demonstrate effects on mortality. A
national endoscopy research group could facilitate this aim.
5. A prospective evaluation of outcome following post-endoscopy placement
and monitoring according to Rockall score is required.
6. A study to refine and validate the co-morbid disease score would be
desirable.
7. New methods for prediction of failure of endoscopic therapy are required.
Measurement of arterial blood flow in the base of an ulcer has been used to
direct endoscopic therapy and to assess the results of therapy (Riemann and
Rosenbaum, 2000). Development of this technique may identify patients in
whom blood flow persists after apparently successful endoscopic treatment.
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